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Technological advancements in radiation therapy (RT) allow the collection of
biomarker data on individual patient response during treatment. Although biomarker
data remains subject to substantial uncertainties, information extracted from this
data may allow the RT plan to be adapted in an informative way. We present a math-
ematical framework that optimally adapts the treatment-length of an RT plan based
on the acquired mid-treatment biomarker information, and also consider the inexact
nature of this information. We formulate the adaptive treatment-length optimization
problem as a 2-stage problem, where after the first stage we acquire information about
model parameters and decisions in stage 2 may depend on this information. Using
Adjustable Robust Optimization (ARO) techniques we derive explicit optimal decision
rules for the stage-2 decisions and solve the optimization problem. The problem
allows for multiple worst-case optimal solutions. To discriminate between these,
we introduce the concept of Pareto Adjustable Robust Optimal (PARO) solutions.
In extensive numerical experiments based on liver cancer patient data, ARO is
benchmarked against several other static and adaptive methods, including robust
optimization with a folding horizon. Results show good performance of ARO both
if acquired mid-treatment biomarker data is exact and inexact. We also investigate
the effect of biomarker acquisition time on the performance of the ARO solution
and the benefit of adaptation. Results indicate that a higher level of uncertainty in
biomarker information pushes the optimal moment of biomarker acquisition backwards.
Keywords: radiation therapy, adjustable robust optimization, nonlinear optimization
1 Introduction
In radiation therapy (RT), the goal is to deliver a curative amount of dose to the target volume(s),
while keeping the dose to all organs-at-risk (OARs) at a minimum. As the radiation beam
delivers energy to all tissues that are in its path, the OARs will (often) inevitably receive some
dose as well. In practice, for all OARs it is determined how much dose they can safely tolerate
before serious complications arise, and the goal is to design a treatment plan that keeps the dose
to all OARs within tolerable limits. In order to do so, the treatment plan is optimized spatially
and temporally.
Spatial optimization exploits the fact that, by mounting the beam head on a gantry, the
tumor can be targeted from various angles. It aims to find the combination of beam angles
and weights that gives the best trade-off between tumor dose conformity and healthy tissue
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sparing. There is a large body of literature on this topic, see for example Shepard et al. (1999),
Ehrgott et al. (2008) for reviews. The result of spatial optimization is a dose distribution, which
indicates how much dose will be received by each voxel (3-dimensional subvolume) of the tumor
and OARs.
Temporal optimization, on the other hand, is concerned with determining the optimal treat-
ment length, or optimal number of treatment fractions. It is based on the concept of fractiona-
tion: compared to tumor cells, healthy tissues have better repair capabilities between fractions
(Fowler 1989, Withers 1985). At the same time, longer treatments give the tumor the possibility
to proliferate, which endangers treatment efficacy. Therefore, there might be an optimal number
of treatment fractions that maintains the best balance between tumor proliferation and OAR
recovery. Treatments with a higher number of fractions and a lower dose per fraction than the
conventional regimen are known as hyperfractionated treatments. Treatments with a lower num-
ber of fractions and a higher dose per fraction than conventional are known as hypofractionated
treatments.
Literature on the fractionation optimization problem is predominantly based on the linear-
quadratic (LQ) model of cell kill, and the related biological effective dose (BED) model Fowler
(1989), Hall and Giaccia (2012). Amongst others, Jones et al. (1995), Armpilia et al. (2004),
Yang and Xing (2005), Mizuta et al. (2012), Bertuzzi et al. (2013), Unkelbach et al. (2013a),
Bortfeld et al. (2015), Saberian et al. (2015, 2016a), Badri et al. (2016), Ajdari and Ghate (2017a)
solve various forms of the fractionation problem, taking into account tumor repopulation, tumor
specific biology, uncertainty and/or multiple normal tissues.
Recently, spatiotemporal optimization has been gaining some attention (Unkelbach et al.
2013b, Unkelbach and Papp 2015, Kim et al. 2015, Ajdari and Ghate 2016, 2017b, Saberian et al.
2017, Adibi and Salari 2018). In these studies, the spatial and the temporal component are
optimized simultaneously. Solving the resulting optimization problems is in general more com-
putationally demanding.
Technological advances in treatment monitoring through imaging and other forms of data
acquisition allow for a more accurate assessment of radiation response (Baumann et al. 2016).
Biological-based adaptive treatments aim to monitor the treatment, acquire mid-treatment
biomarkers, and adapt the remainder of the treatment course accordingly. From a mathematical
optimization perspective, this presents an adaptive optimization problem.
Literature on biological-based adaptive treatment optimization is limited. Ghate (2011)
and Kim et al. (2012) propose a theoretical stochastic control framework to optimally adapt
the beam intensities over a fixed number of fractions, based on hypothetically-observed tumor
states. Saberian et al. (2016b) concretize this theoretical framework, using simulated hypoxia
status as biomarker. Ajdari et al. (2018) considers a mathematical model where they adaptively
determine the optimal number of treatment fractions, in order to minimize the total number of
tumor cells remaining (TNTCR) at the end of the treatment course. After each fraction they
observe the tumor cell density in each voxel, and use this to re-optimize a spatiotemporal model.
In robust optimization terminology, this is known as a folding horizon (FH) approach.
The limited availability and accuracy of required biomarkers poses a primary challenge for
adaptive treatments (Baumann et al. 2016). Any biomarker information from data gathered
during treatment remains subject to uncertainties, stemming from both measurement errors
and the inexactness in the translation of measured data to model parameters. Therefore, it is
crucial that any adaptive treatment optimization takes this into account. Ajdari et al. (2019)
provide an overview of relevant mathematical (optimization) tools. Robust Optimization (RO)
(see, e.g., Ben-Tal et al. (2009), Bertsimas et al. (2011), Gorissen et al. (2015) for an overview)
has been the predominant method for dealing with uncertainties in radiation therapy treatment
planning. Amongst others, it has been applied for dealing with motion uncertainty (Chan et al.
2006, Bortfeld et al. 2008) and delineation uncertainty (Balvert et al. 2019).
Adjustable Robust Optimization (ARO) (Ben-Tal et al. 2004, Yanıkoğlu et al. 2019) is an
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extension of RO that takes into account the flow of information over time and exploits the
fact that some decisions need to be taken only after the data has (partially) revealed itself. In
the standard paradigm, ARO assumes that the revealed data is exact; de Ruiter et al. (2017)
introduces ARO methodology for the case when revealed data is not exact but provides only an
estimate of the true parameters.
This paper considers robust adaptive treatment-length optimization based on mid-treatment
acquired biomarker information, taking into consideration the inexact nature of the acquired
biomarker data. Our main contributions are:
• We develop mathematical tools based on ARO that enable us to (i) optimally adapt the
treatment length after acquiring mid-treatment biomarker information, (ii) analyze the
influence of biomarker information uncertainty. To the best of our knowledge, this is the
first application of ARO to an RT problem.
• We present explicit optimal decision rules for a difficult (non-convex, mixed-integer) yet
practically relevant ARO problem.
• We show that there are multiple optimal solutions for the worst-case scenario, and that
these perform very differently in other scenarios. To handle this, we introduce the con-
cept of Pareto Adjustable Robustly Optimal (PARO) solutions, a generalization of Pareto
Robustly Optimal (PRO) solutions (Iancu and Trichakis 2013) to two-stage robust opti-
mization problems. In case the acquired biomarker data is exact, PARO solutions are
obtained.
• We perform a computational study to determine the optimal timing of acquiring biomarker
information in case biomarker quality improves over time. Later biomarker acquisition also
limits adaptation possibilities, and the optimal balance depends on the improvement rate.
The remainder of this paper is organized as follows. Section 2 introduces the BED model and the
nominal treatment-length optimization problem. Section 3 introduces the adaptive treatment-
length optimization problem under the assumption of exact biomarker information and solves
this using ARO techniques. Section 4 generalizes this to inexact biomarker information. Section
5 reports and discusses results of the numerical experiments. Finally, Section 6 states several
concluding remarks.
Notation. All variables and constants are 1-dimensional (belong to R or N) unless indicated
otherwise. In functions, a semicolon (;) is used to separate variables and constant arguments
from uncertain parameters. Optimal solutions to optimization problems are indicated with an
asterisk (∗). Properties of optimal solutions to optimization problems have calligraphic font
(e.g., ARO) to distinguish them from methods with the same or similar abbreviations.
2 The BED model
The BED model (Fowler 1989, 2010, Hall and Giaccia 2012) states that the biological effect of
an N -fraction dose sequence d = (d1, . . . , dN ) (in Gray (Gy)) delivered to a tumor volume is
given by
BED =
N∑
t=1
dt +
1
α/β
N∑
t=1
d2t , (1)
which is a model governed by a single parameter, the α/β ratio, which signifies the fractionation
sensitivity of the tumor tissue. The generalized dose-sparing factor σ denotes the fraction of
mean tumor dose that the OAR receives on average. This enables expressing the OAR dose
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in terms of the tumor dose: dose to the OAR in fraction t is given by σdt. For notational
convenience, let τ (for tumor) and ρ (for risk) denote the inverse α/β ratio of the tumor and
OAR volume, respectively. Mizuta et al. (2012) consider the problem of minimizing OAR BED
subject to a lower bound BEDpresT on tumor BED. The number of fractions N is restricted to
be at most Nmax. The problem reads
min
d,N
σ
N∑
t=1
dt + ρσ
2
N∑
t=1
d2t (2a)
s.t.
N∑
t=1
dt + τ
N∑
t=1
d2t ≥ BEDpresT (2b)
d1, . . . , dN ≥ 0, N ∈ {1, . . . , Nmax}. (2c)
Let (d∗, N∗) denote the optimal solution to (2). A simple analysis in Mizuta et al. (2012) reveals
the following important result:
N∗ =
{
1 if τ ≥ σρ
Nmax and d∗1 = . . . = d
∗
Nmax otherwise.
(3)
In both cases the optimal dose d∗ is such that (2b) is active. It can be shown that the same
result holds if we maximize tumor BED subject to an upper bound on OAR BED (Bortfeld et al.
2015). Similar results have been derived for amongst others heterogeneous dose distributions
(Unkelbach et al. 2013a) and multiple normal tissues (Saberian et al. 2015). However, all of
these approaches assume the tumor and OAR radiosensitivity parameters τ and ρ are known
exactly. There is much research on the α/β ratios for different tumor sites (Tai et al. 2008,
Son et al. 2013, Klement 2017) and OAR sites (van Leeuwen et al. 2018), but they remain sub-
ject to considerable uncertainties. Badri et al. (2016) takes a stochastic programming approach,
assuming a normal distribution for τ . Ajdari and Ghate (2017a) takes a robust optimization
approach. However, if biomarker information acquired during treatment provides more accu-
rate information on τ than what was available at the start of the treatment, a static stochastic
programming or robust optimization approach may be overly conservative.
3 ARO: Biomarkers provide exact information
We present an adjustable robust optimization approach that optimally adjusts the remainder of
the treatment once biomarker information has provided the true value of parameters τ and ρ.
3.1 Problem formulation
In order to establish a meaningful model for the adjustable robust optimization approach, we
restrict the dose sequence d = (d1, . . . , dNmax) in several ways. We set a minimum number of
fractions Nmin. Furthermore, we assume there is a single moment N1 where we can adapt the
treatment. The dose per fraction in the first N1 fractions is assumed to be the same, denote this
by d1. Variable N2 denotes the number of fractions after adaptation; also these fractions have
equal dose, denoted by d2. This implies
N2 ∈
{
Nmin2 , . . . , N
max
2
}
, (4)
withNmin2 = max{1, Nmin−N1} andNmax2 = Nmax−N1. We additionally set the constraint that
d1, d2 ≥ dmin, for some predetermined value dmin. Lastly, we set a maximum dose per fraction
in stage 1, to avoid delivering dosages in stage 1 that severely restrict adaptation possibilities in
stage 2. We will later impose some restrictions on the allowed combinations of dmin, dmax1 and
Nmax2 . Figure 1 provides a schematic overview of the situation. We wish to maximize the tumor
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0 fx N1 fx N1 +N2 fx
Stage 1 Stage 2
d1 Gy/fx
Observe (ρ, τ )
d2 Gy/fx
Figure 1: Schematic overview of the model of Section 3. There are 3 variables: d1, d2 and N2. First, we
deliver N1 fractions of dose d1 per fraction. After this, we observe (ρ, τ). Subsequently, we deliver N2
fractions of dose d2 per fraction.
BED, subject to the constraint that the BED to the OAR is below the tolerance level BEDtol,
given by
BEDtol(ρ) = ϕD
(
1 +
ϕD
T
ρ
)
, (5)
i.e., the OAR is known to tolerate a total dose of D Gy if delivered in T fractions under dose
shape factor ϕ. The dose shape factor is a parameter characterizing the spatial heterogeneity of
a dose distribution, for more details see Perkó et al. (2018). Note that BEDtol(ρ) is a function
of uncertain parameter ρ.
After delivering N1 fractions we observe the true (ρ, τ). At the time that the stage-1 dose
per fraction d1 has to be decided, it is only known that (ρ, τ) belongs to some uncertainty set
Z. Put together, the Exact Data Problem (EDP) reads:
max
d1,d2(ρ,τ),N2(ρ,τ)
min
(ρ,τ)∈Z
N1d1 +N2(ρ, τ)d2(ρ, τ) + τ(N1d
2
1 +N2(ρ, τ)d2(ρ, τ)
2) (6a)
s.t. σ(N1d1 +N2(ρ, τ)d2(ρ, τ)) + ρσ
2(N1d
2
1 +N2(ρ, τ)d2(ρ, τ)
2)
≤ BEDtol(ρ), ∀(ρ, τ) ∈ Z
(6b)
N2(ρ, τ) ∈ {Nmin2 , . . . , Nmax2 }, ∀(ρ, τ) ∈ Z (6c)
d2(ρ, τ) ≥ dmin, ∀(ρ, τ) ∈ Z (6d)
dmin ≤ d1 ≤ dmax1 . (6e)
The value for the stage-1 dose d1 has to be decided before the value of (ρ, τ) is revealed; in ARO
this is also commonly referred to as a here-and-now variable or decision. The values stage-2 dose
d2 and stage-2 number of fractions N2 need to be decided only after (ρ, τ) is revealed as they
may depend on the values of these parameters. Hence, they are written as functions d2(ρ, τ) and
N2(ρ, τ) of the uncertain parameters (ρ, τ). In ARO such variables are also commonly referred
to as wait-and-see variables or decisions. In this paper, we will adhere to the terms stage 1 and
stage 2, however.
We assume box uncertainty of the form:
Z :=
{
(ρ, τ) : ρL ≤ ρ ≤ ρU , τL ≤ τ ≤ τU
}
, (7)
with 0 < ρL < ρU and 0 < τL < τU . It is assumed that there is a nominal scenario, e.g.,
parameter values τ¯ and ρ¯ derived from literature. The first observation we make in (6) is that
the objective is increasing in parameter τ , so in any worst-case realization it will hold that
τ = τL. This observation has consequences for what uncertainty sets Z need to be considered.
Due to (3), one can in general distinguish three cases for uncertainty set Z and parameter σ:
Case 1) σρL ≥ τL: According to (3), for any realization (with τ = τL) it is optimal to deliver
the minimum number of fractions in stage 2.
Case 2) σρU ≤ τL: According to (3), for any realization (with τ = τL) it is optimal to deliver
the maximum number of fractions in stage 2.
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Case 3) σρL < τL < σρU : In the scenario (ρL, τL), it is optimal to deliver the maximum
number of fractions in stage 2 according to (3). In the scenario (ρU , τL), it is optimal
to deliver the minimum number of fractions in stage 2 according to (3).
In case 1 and 2, (6) is easily solved by plugging in the (worst-case) optimal value for N2, and
solving the resulting 2-variable optimization problem. Therefore, only Case 3 is of interest and
in the remainder of this paper it is assumed that
σρL < τL < σρU . (8)
Problem (6) is a 2-stage non-convex mixed-integer ARO problem, which are generally hard to
solve. Nevertheless, due to the small number of variables the problem can be solved to optimality.
3.2 Optimal decision rules and worst-case solution
Before we solve (6), we first need some additional definitions and assumptions. The remaining
BED tolerance level of the OAR, if N ′ fractions with dose d′ have been administered, is given
by
B(d′, N ′; ρ) = BEDtol(ρ)− σd′N ′ − ρσ2(d′)2N ′. (9)
Subsequently, define the function
g(d′, N ′, N ′′; ρ) :=
−1 +
√
1 + 4ρN ′′B(d
′, N ′; ρ)
2σρ
. (10)
The value of g can be interpreted as the maximum dose that can be delivered in N ′′ fractions if
already N ′ fractions of dose d′ are (scheduled to be) delivered. It is obtained by solving (6b) for
d1 or d2. Functions of this form will be used frequently throughout the remainder of this paper.
The following assumption on the relation between dmin, dmax1 and N
max
2 makes sure that
for a given optimal number of fractions, it is feasible to deliver that number of fractions with
minimum dose.
Assumption 1. It holds that
dmin ≤ dmax1 ≤ min
{
g(dmin, Nmin2 , N1; ρL), g(d
min, Nmax2 , N1;
τL
σ
), g(dmin, Nmax2 , N1; ρU )
}
(11)
The particular form of the upper bound on dmax1 will become clear later. Numerical experiments
indicate that results are not very sensitive to the choices of dmin and dmax1 . In order to solve (6),
we take three steps:
Step 1) Eliminate variable d2(ρ, τ) by writing it as a function of d1 and N2(ρ, τ).
Step 2) Determine the optimal N2 as a function of (ρ, τ).
Step 3) Solve the resulting problem of variable d1.
In what follows, we give a detailed explanation of each of these steps.
Step 1: eliminate variable d2(ρ, τ)
Let (d∗1, d
∗
2(ρ, τ), N
∗
2 (ρ, τ)) denote an optimal solution to (6). In the optimum, constraint (6b)
holds with equality because it is the only dose-limiting constraint. Solving for d2 yields
d∗2(d1, N2; ρ) = g(d1, N1, N2; ρ). (12)
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This suggests the following objective function for given (ρ, τ):
f(d1, N2; ρ, τ) :=


N1d1 +N2g(d1, N1, N2; ρ)
+τ
(
N1d
2
1 +N2g(d1, N1, N2; ρ)
2) if d1 ∈ [0, g(0, 0, N1 ; ρ)]
−∞ otherwise,
(13)
where, for given ρ, the value g(0, 0, N1; ρ) is the maximum dose that can be delivered in stage
1 due to the nonnegativity restriction on the stage-2 dose. From Assumption 1 it follows that
g(0, 0, N1; ρ) ≥ dmax1 for all (ρ, τ) ∈ Z. According to Lemma 1 in Appendix B, function f is
either convex, concave or constant in d1.
Due to the above steps, EDP (6) is equivalent to
max
d1,N2(ρ,τ)
min
(ρ,τ)∈Z
f(d1, N2(ρ, τ); ρ, τ) (14a)
s.t. g(d1, N1, N2(ρ, τ); ρ) ≥ dmin, ∀(ρ, τ) ∈ Z (14b)
N2(ρ, τ) ∈ {Nmin2 , . . . , Nmax2 }, ∀(ρ, τ) ∈ Z (14c)
dmin ≤ d1 ≤ dmax1 . (14d)
Step 2: determine the optimal N2(ρ, τ).
Let X(ρ, τ) denote the feasible region defined by constraints (14b)-(14d) for fixed (ρ, τ). First,
we define adjustable robust feasibility of a solution.
Definition 1 (Adjustable robustly feasible). A pair (d1, N2(·)) is adjustable robustly feasible
(ARF) to (14) if (d1, N2(ρ, τ)) ∈ X(ρ, τ) for all (ρ, τ) ∈ Z.
Subsequently, define adjustable robust optimality of a solution.
Definition 2 (Adjustable robustly optimal (d1, N2(·))). A pair (d1, N2(·)) is adjustable robustly
optimal (ARO) to (14) if it is ARF and there does not exist an ARF pair (d¯1, N¯2) such that
min
(ρ,τ)∈Z
f(d1, N2(ρ, τ); ρ, τ) < min
(ρ,τ)∈Z
f(d¯1, N¯2(ρ, τ); ρ, τ). (15)
We also define the concept ARO for the stage-1 decisions d1 or the stage-2 decision (rules) N2(·)
only:
Definition 3 (Adjustable robustly optimal d1 and/or N2(·)).
3.1 A stage-1 decision d1 is ARO to (14) if there exists a decision rule N2(·) such that
(d1, N2(·)) is ARO to (14).
3.2 A stage-2 decision (rule) N2(·) is ARO to (14) if there exists a stage-1 decision d1 such
that (d1, N2(·)) is ARO to (14).
Although definitions are given for (14), due to (12) these readily extend to adjustable robust
feasibility/optimality for the original EDP (6). The following theorem, similar to the result (3),
states the optimal stage-2 decision rules.
Theorem 1. The decision rule
N∗2 (ρ, τ) =
{
Nmin2 if τ ≥ σρ
Nmax2 otherwise,
(16)
is an ARO solution for N2(·) in (14). It is the unique ARO solution if τ 6= σρ.
Proof. See Appendix A.1.
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ρL ρU
τL
τU
τ = σρ
Zmin
Zmax
ρ
τ
Figure 2: Split of uncertainty set Z according to (18). The circles indicate the locations of the candidate
worst-case scenarios for (14).
By (12), this implies that the unique optimal stage-2 decision rule for d2 as a function of d1 and
the uncertain parameters is
d∗2(d1; ρ, τ) =
{
g(d1, N1, Nmin2 ; ρ) if τ ≥ σρ
g(d1, N1, Nmax2 ; ρ) otherwise.
(17)
Clearly, these decision rules are non-linear, and in fact split the uncertainty region in two parts:
one where it is optimal to deliver the minimum number of fractions Nmin2 in stage 2, and one
where it is optimal to deliver the maximum number of fractions Nmax2 in stage 2. This suggests
splitting the uncertainty set as follows:
Zmin = Z ∩ {τ ≥ σρ} (18a)
Zmax = Z ∩ {τ < σρ}. (18b)
An illustration is provided in Figure 2.
Step 3: solve the resulting problem of variable d1.
It remains to determine the optimal dose per fraction in stage 1. Using (16) and (17), we can
reformulate (14) to a problem of only variable d1. Note that uncertain parameter τ plays no
other role than to determine the optimal number of stage-2 fractions N∗2 . Uncertain parameter
τ appears only in the objective and function f is increasing in τ , so it is sufficient to consider
only those observations with τ = τL.
In order to reformulate (14), we make use of the properties of g and f in Lemma 3 in
Appendix B. In particular, Lemma 3b states that function f is either increasing or decreasing
in ρ for fixed d1. Hence, if we move (14a) to a constraint and split according to (18), for both
Zmin and Zmax it is sufficient to consider the constraint for the highest and lowest value of ρ
in the uncertainty set. With τ = τL, this yields the scenarios (ρL, τL) and (
τL
σ , τL) for Z
min
and ( τLσ , τL) and (ρU , τL) for Z
max. Due to Lemma 3a, we find the same candidate worst-case
scenarios for constraint (14b).
Therefore, the three candidate worst-case scenarios are (ρL, τL), (ρU , τL) and (
τL
σ , τL); their
locations are indicated in Figure 2. By Lemma 1, the objective value in the third scenario is
equal to K, with
K =
1
σ
B
(
0, 0,
τL
σ
)
. (19)
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d1
q
f(d1, N
min
2 ; ρL, τL)
f(d1, N
max
2 ; ρU , τL)
K
Figure 3: Illustration of (20). The solid, dashed and dotted lines represent constraints (20b), (20c) and
(20d), respectively. Locations where multiple of these constraints are binding are indicated by circles.
Putting everything together, we conclude that if (d∗1, d
∗
2(ρ, τ), N
∗
2 (ρ, τ)) solves the EDP (6) then
there exists a q∗ ∈ R+ such that (d∗1, q∗) is an optimal solution to
max
d1,q
q (20a)
s.t. q ≤ f(d1, Nmin2 ; ρL, τL) (20b)
q ≤ f(d1, Nmax2 ; ρU , τL) (20c)
q ≤ K (20d)
dmin ≤ d1 ≤ dmax1 . (20e)
Conversely, if (d∗1, q
∗) is an optimal solution to (20) and d∗2, N
∗
2 are given by (16) and (17),
respectively, then (d∗1, d
∗
2, N
∗
2 ) solves (6). Hence, (20) and EDP (6) are equivalent.
According to Lemma 1, the RHS of (20b) and (20c) is convex and concave in d1, respectively.
Hence, (20) asks to find the value of d1 that maximizes the minimum of a univariate convex (20b),
concave (20c) and constant (20d) function on a closed interval (20e). Lemma 2 in Appendix B
provides information on the intersection points of the functions (20b)-(20d). Consequently, the
optimal solution(s) to (20) is/are easily found.
Figure 3 illustrates a possible instance of (20), displaying constraints (20b)-(20d). In this
case, the set of optimal solutions is the union of the two intervals for d1 where constraint (20d)
is active. Dose constraints (20e) may cut off part of these intervals. If due to constraint (20e)
both these intervals are infeasible, the optimum is at one of the boundaries for d1.
3.3 Pareto adjustable robustly optimal solutions
Figure 3 illustrates that it is possible that there are multiple optimal solutions to (20). These
solutions are ARO stage-1 solutions to the EDP (6). In general, in case there are multiple ARO
solutions these may perform vastly different if a non-worst-case scenario realizes (de Ruiter et al.
2016). Iancu and Trichakis (2013) studies static robust optimization problems with multiple ro-
bustly optimal solutions, and introduce the concept of Pareto robustly optimal (PRO) solutions.
A robustly optimal solution is called PRO if there is no other robustly feasible solution that is
has equal or better objective value for all scenarios in the uncertainty set, while being strictly
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better for at least one scenario. Non-PRO solutions are dominated by at least one PRO solu-
tion and are therefore not desired. The concept of Pareto robust optimality closely resembles
the concept of Pareto efficiency in multi-criteria optimization (MCO). In MCO, Pareto efficient
solutions can only be improved in one criteria at the cost of a deterioration in another criteria.
Only Pareto efficient solutions are of interest, and the overall goal in MCO is to compute this
set of solutions (known as the Pareto surface).
We generalize the concept of Pareto robust optimality to 2-stage adjustable robust optimiza-
tion problems.
Definition 4 (Pareto adjustable robustly optimal (d1, N2(·))). An ARO pair (d1, N2(·)) is
Pareto adjustable robustly optimal (PARO) to (14) if there is no pair (d¯1, N¯2(·)) that is ARO to
(14) and satisfies
f(d1, N2(ρ, τ); ρ, τ) ≥ f(d¯1, N¯2(ρ, τ); ρ, τ) ∀(ρ, τ) ∈ Z (21a)
f(d1, N2(ρ¯, τ¯); ρ¯, τ¯) > f(d¯1, N¯2(ρ¯, τ¯); ρ¯, τ¯) for some (ρ¯, τ¯) ∈ Z. (21b)
We also define the concept PARO for the stage-1 decision d1 or the stage-2 decision (rule) N2(·)
only.
Definition 5 (Adjustable robustly optimal d1 and/or N2(·)).
5.1 A stage-1 decision d1 is PARO to (14) if there exists a decision rule N2(·) such that
(d1, N2(·)) is PARO to (14).
5.2 A stage-2 decision (rule) N2(·) is PARO to (14) if there exists a stage-1 decision d1 such
that (d1, N2(·)) is PARO to (14).
If there are multipleARO solutions, we wish to pick one that is PARO. In Iancu and Trichakis
(2013) it is shown for linear optimization that, if we optimize over the robustly optimal solu-
tions for a second criterion (scenario) that is in the relative interior of the uncertainty set, the
resulting solution(s) are PRO. In a similar fashion PARO solutions to the current problem can
be found.
Let XARO denote the set of ARO solutions to (20). It turns out that consecutively optimizing
over an auxiliary scenario where hyperfractionation is optimal and an auxiliary scenario where
hypofractionation is optimal yields a set of PARO solutions. Let (ρaux-min, τaux-min) ∈ int(Zmin),
where int(·) is the interior operator. Define the auxiliary optimization problem for the hypofrac-
tionation scenario:
max
d1∈XARO
f
(
d1, N
min
2 ; ρ
aux-min, τaux-min
)
. (22)
Denote the set of optimal solutions by Xaux-min. Similarly, let (ρaux-max, τaux-max) ∈ int(Zmax).
Define the auxiliary optimization problem for the hyperfractionation scenario:
max
d1∈Xaux-min
f
(
d1, N
max
2 ; ρ
aux-max, τaux-max
)
. (23)
Note that it uses Xaux-min as input, i.e., we solve the auxiliary problems consecutively. Denote
the set of optimal solutions by XPARO.
Theorem 2. All solutions in XPARO are PARO.
Proof. See Appendix A.2.
Solving (22) or (23) asks to maximize a strictly convex or strictly concave function over a
feasible set consisting of a small number of intervals or points. Hence, these auxiliary problems
are easily solved. Note that the second auxiliary problem is only relevant if the first auxiliary
problem has multiple optimal solutions. Switching their order, and optimizing (22) over the set
Xaux-max may lead to different solutions, and these are also PARO. The two-step approach is
necessary; numerical results show that optimizing over one auxiliary scenario may indeed yield
non-PARO solutions.
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4 ARO: Biomarkers provide inexact information
In this section we present an adjustable robust optimization approach to solve a more realistic
version of the adaptive treatment-length problem. Because in practice it is impossible to exactly
determine the α/β parameters from biomarker data, any values for the α/β parameters obtained
during treatment are inexact. This section presents a model that accounts for uncertainty in
biomarker observations.
4.1 Problem formulation
The setup for the ARO problem with inexact data is based on de Ruiter et al. (2017). After N1
fractions we obtain an estimate (ρˆ, τˆ ) for (ρ, τ), the inverse α/β parameters for the OAR and
the tumor. It is still assumed that (8) holds for uncertainty set Z. Furthermore, we assume that
(ρ, τ), (ρˆ, τˆ) ∈ Z (as defined in (7)) and that (ρˆ, τˆ )− (ρ, τ) ∈ Zˆ, with
Zˆ = {(ερ, ετ ) ∈ R2 : |ερ| ≤ rρ, |ετ | ≤ rτ}. (24)
Here rρ and rτ are parameters that define the accuracy of the estimate/observation (ρˆ, τˆ ). This
can also be written as (ρ, τ) ∈ {(ρˆ, τˆ)} + Zˆ, which is the Minkowski sum of a singleton and a
set. For given observation (ρˆ, τˆ), the new upper and lower bounds for (ρ, τ) are given by
τˆL = max{τL, τˆ − rτ}, τˆU = min{τU , τˆ + rτ} (25a)
ρˆL = max{ρL, ρˆ− rρ}, ρˆU = min{ρU , ρˆ+ rρ}. (25b)
Define
U = {(ρ, τ, ρˆ, τˆ ) : (ρ, τ), (ρˆ, τˆ ) ∈ Z, (ρˆ, τˆ)− (ρ, τ) ∈ Zˆ}. (26)
The set U contains all possible observation-realization pairs. Lastly, we remove Assumption
1 and impose a different (slightly stricter) assumption on the relation between dmin, dmax1 and
Nmax2 .
Assumption 2. It holds that dmin ≤ dmax1 and
dmax1 ≤ min
{
g(dmin1 , N
min
2 , N1; ρL), g(d
min
1 , N
max
2 , N1;max{ρL, τLσ − 2rρ}), g(dmin1 , Nmax2 , N1; ρU )
}
. (27)
The inexact data problem (IDP) analogous to (6) is given by
max
d1,d2(ρˆ,τˆ),N2(ρˆ,τˆ)
min
(ρ,τ,ρˆ,τˆ)∈U
N1d1 +N2(ρˆ, τˆ )d2(ρˆ, τˆ) + τ(N1d
2
1 +N2(ρˆ, τˆ)d2(ρˆ, τˆ )
2), (28a)
s.t. σ(N1d1 +N2(ρˆ, τˆ)d2(ρˆ, τˆ )) + ρσ
2(N1d
2
1 +N2(ρˆ, τˆ)d2(ρˆ, τˆ)
2)
≤ BEDtol(ρ), ∀(ρ, τ, ρˆ, τˆ ) ∈ U
(28b)
N2(ρˆ, τˆ) ∈ {Nmin2 , . . . , Nmax2 }, ∀(ρ, τ, ρˆ, τˆ ) ∈ U (28c)
d2(ρˆ, τˆ) ≥ dmin, ∀(ρ, τ, ρˆ, τˆ) ∈ U (28d)
dmin ≤ d1 ≤ dmax1 . (28e)
Let X(ρ, τ, ρˆ, τˆ) denote the feasible region defined by constraints (28b)-(28e) for fixed (ρ, τ, ρˆ, τˆ).
For stage-2 variables d2(ρˆ, τˆ) and N2(ρˆ, τˆ) it is indicated that they are a function of the obser-
vations (ρˆ, τˆ) instead of the uncertain parameters (ρ, τ).
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4.2 Optimal decision rules and conservative approximation
Depending on both the observed (ρˆ, τˆ ) and the quality of the biomarker observation (i.e., rρ and
rτ ), we may be able to immediately determine the optimal value for N2. Therefore, we split the
uncertainty set for the observations (ρˆ, τˆ). Define
ZminID = {(ρˆ, τˆ) ∈ Z : τˆL ≥ σρˆU} (29a)
Z intID = {(ρˆ, τˆ) ∈ Z : σρˆL < τˆL < σρˆU} (29b)
ZmaxID = {(ρˆ, τˆ) ∈ Z : τˆL ≤ σρˆL}, (29c)
so that Z = ZminID ∪ Z intID ∪ ZmaxID . Figure 4 provides an illustration. The split is such that if
(ρˆ, τˆ) ∈ ZminID or (ρˆ, τˆ) ∈ ZmaxID only Nmin2 resp. Nmax2 fractions can be optimal in stage 2.
Subset Z intID is the area between the red lines. If (ρˆ, τˆ) ∈ Z intID both Nmin2 and Nmax2 fractions in
stage 2 may be optimal for the true (ρ, τ). Before this is formalized in a theorem, we state two
definitions.
Definition 6 (Adjustable robust feasibility). A tuple (d1, d2(·), N2(·)) is adjustable robustly
feasible (ARF) to (28) if (d1, d2(ρˆ, τˆ ), N2(ρˆ, τˆ )) ∈ X(ρ, τ, ρˆ, τˆ ) for all (ρ, τ, ρˆ, τˆ ) ∈ U .
Definition 7 (Adjustable robust optimality given d1). For given d1, a pair (d2(·), N2(·)) is
adjustable robustly optimal (ARO) to (28) if (d1, d2(·), N2(·)) is ARF to (28) and there does not
exist a pair (d¯2(·), N¯2(·)) such that (d1, d¯2(·), N¯2(ρ, τ)) is ARF to (28) and
min
(ρ,τ,ρˆ,τˆ)∈U
N1d1 +N2(ρˆ, τˆ )d2(ρˆ, τˆ ) + τ(N1d
2
1 +N2(ρˆ, τˆ)d2(ρˆ, τˆ)
2)
< min
(ρ,τ,ρˆ,τˆ)∈U
N1d1 + N¯2(ρˆ, τˆ )d¯2(ρˆ, τˆ ) + τ(N1d
2
1 + N¯2(ρˆ, τˆ)d¯2(ρˆ, τˆ)
2).
(30)
The following theorem states the optimal stage-2 decision rules for a given value of d1.
Theorem 3. Let d1 be the stage-1 decision of (28). The decision rules
N∗2 (d1; ρˆ, τˆ ) =


Nmin2 if (ρˆ, τˆ ) ∈ ZminID
arg max
N2∈{N
min
2
,...,Nmax
2
}
min{f(d1,N2;ρˆL,τˆL),f(d1,N2;ρˆU ,τˆL)} if (ρˆ, τˆ ) ∈ Z intID
Nmax2 if (ρˆ, τˆ ) ∈ ZmaxID ,
(31)
and
d∗2(d1; ρˆ, τˆ) = min{g(d1, N1, N∗2 (d1; ρˆ, τˆ ); ρˆL), g(d1, N1, N∗2 (d1; ρˆ, τˆ ); ρˆU )}, (32)
are ARO solutions for N2(·) and d2(·) in (28) for the given d1.
Proof. See Appendix A.3.
The worst-case optimal decision rule (31) may yield an intermediate value if (ρˆ, τˆ) ∈ Z intID . If
rρ and rτ are zero, i.e., we have exact data, then it holds that τˆL = τ and ρˆL = ρˆU = ρ. Hence,
the two functions f in the RHS of (31) are equal, and the optimal N∗2 is the one that maximizes
the resulting function. One can verify that this does not depend on d1. Hence, in case of exact
data Theorem 3 is equivalent to Theorem 1.
It turns out that, after plugging in (31) and (32), and splitting the uncertainty set according
to (29), it is not apparent how to determine the optimal stage-1 decision d∗1 for (28). In Appendix
A.4 the following lower bound problem to (28), named the Approximate Inexact Data Problem
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ρL ρU
τL
τU
ZminID
ZintID
ZmaxID
ρ
τ
τ = σρ
τ = σρˆU
τ = σρˆL
Figure 4: The uncertainty set Z (solid lines) for (ρˆ, τˆ ) is split into Zmin
ID
, Z int
ID
, Zmax
ID
, according to (29).
Subset Z int is the area between the dotted and dash-dotted curves. If (ρˆ, τˆ ) ∈ Z int both Nmin2 and Nmax2
fractions in stage 2 may be optimal for the true (ρ, τ). If (ρˆ, τˆ ) ∈ Zmin or (ρˆ, τˆ) ∈ Zmax only Nmin2 resp.
Nmax2 fractions can be optimal in stage 2.
(AIDP), is derived:
max
d1,q
q (33a)
s.t. q ≤ f(d1, Nmin2 ; ρL, τL) (33b)
q ≤ f(d1, Nmax2 ; ρU , τL) (33c)
q ≤ K (33d)
q ≤ p(d1) (33e)
dmin ≤ d1 ≤ dmax1 . (33f)
Compared to (14) for exact biomarker observations, problem (33) has the added constraint
(33e); a piecewise convex-concave function p(d1) defined by (B.68) in Appendix A.4. Lemmas
1, 2 and 5 in Appendix B provide information on the shape and intersection points of constraint
functions (33b)-(33e). Consequently, the optimal solution(s) is/are easily obtained.
From an optimal solution (d∗1, q
∗) to AIDP (33) an ARF solution to the original IDP (28)
can be constructed by omitting q∗ and using stage-2 decisions (31) and (32). This solution is
ARF because AIDP is a conservative approximation of IDP.
Figure 5 illustrates a possible instance of (33), displaying constraints (33b)-(33e). In this
case, optimal solutions are locations where (33d) and (33e) are both binding, indicated by the
circles. Dose constraints (33f) may cut off (some of) these points. If due to constraint (33f) none
of the circles are feasible, the optimum is at one of the boundaries for d1. Constraint (33e) is
the only conservative constraint in (33). Hence, only if the feasible values for d1 are such that
none of the circles in Figure 5 are feasible and constraint (33e) is binding, it is possible that the
optimal value of (33) is strictly worse than that of (28).
4.3 Pareto robustly optimal solutions to conservative approximation
Figure 5 also illustrates that it is possible that there are multiple optimal solutions to the AIDP
(33). Because the AIDP provides a conservative approximation to IDP (28), optimizing over
auxiliary scenario(s), as in Section 3, does not necessarily yield a stage-1 decision d1 that is
PARO to the original IDP. It turns out that a PRO solution to AIDP is obtained from the set of
robustly optimal solutions to AIDP if we consecutively optimize for two auxiliary observations
such that any worst-case realization is in the interior of set Zmin resp. Zmax. Two important
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d1
q
f(d1, N
min
2 ; ρL, τL)
f(d1, N
max
2 ; ρU , τL)
K
p(d1)
Figure 5: Illustration of (33). Compared to the case with exact data (Figure 3), the thick black curve
(constraint (33e)) is extra. The solid, dashed and dotted lines represent constraints (33b), (33c) and
(33d), respectively. Locations where multiple constraints are binding are indicated by circles.
remarks are in place here. First, a PRO solution to AIDP need not be a PARO solution to IDP,
even if it is worst-case optimal to IDP. Second, the required auxiliary scenarios need not exist;
their existence depends on the values of rρ and rτ . Hence, further details are omitted.
5 Numerical results
This section presents numerical results of the methods presented in Sections 3 and 4. First,
Section 5.1 describes the benchmark methods against which we compare the ARO method for
EDP and IDP, and Section 5.2 describes the setup of the numerical experiments.
5.1 Benchmark static and folding horizon methods
We analyze the performance of the static and folding horizon nominal method (NOM and
NOM-FH), the static and folding horizon robust optimization method (RO and RO-FH) and
the adjustable robust optimization method (ARO). In the folding horizon approaches only the
stage-1 decisions are implemented, and the model is re-optimized for the second stage once the
biomarker information is revealed.
The static method NOM optimizes for the nominal parameter values τ¯ and ρ¯ and disregards
any uncertainty and adaptability. This method is the same for both EDP and IDP. In stage
2, NOM-FH solves the nominal problem under the assumption that the obtained biomarker
estimate is exact (which is a false assumption for IDP). This method does not guarantee robust
feasible solution (feasible for all (ρ, τ) ∈ Z) nor a robustly optimal solution (RO; optimal for the
worst-case realization (ρ, τ) ∈ Z).
The static method RO optimizes for the worst-case realization of (τ, ρ) in the uncertainty set
Z, and disregards adaptability. For EDP the method RO-FH solves the same nominal problem
as NOM-FH in stage 2; for IDP it solves a static robust optimization problem in stage 2. The
uncertainty set is defined by the accuracy of the biomarker information. RO and RO-FH both
guarantee an RO solution.
One may add a folding horizon component to ARO (for either EDP or AIDP). This may
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Method
Problem NOM NOM-FH RO RO-FH ARO
EDP - - RO RO PARO
IDP - - RO RO ARF
Table 1: Guaranteed solution properties of the five methods.
Uncertainty set ρ interval τ interval
1 [0.125,0.375] [0.1875,0.3125]
2 [0.125,0.375] [0.125, 0.375]
Table 2: Uncertainty sets Z used in the experiments.
improve the results in case a suboptimal stage-2 decision rule is used. However, as shown in
Sections 3.2 and 4.2, the used stage-2 decision rules are optimal for any realized scenario (and
for given stage-1 decision d1 in case of inexact information). Hence, adding a folding horizon
component would not change results.
Table 1 provides an overview of the guaranteed solution properties of the methods. It is
important to note that in case of inexact biomarker data (IDP) the methods RO and RO-
FH guarantee an RO solution, whereas ARO guarantees only an ARF solution via solving the
approximate problem AIDP. Depending on the approximation quality, the ARF solution may
be close or equal to an ARO solution. Next to these five methods, we also report the results
for the perfect information optimum (PI). This is the attainable optimum if from the start of
the first fraction the true (ρ, τ) is exactly known. It can be formulated by taking the nominal
problem and replacing the nominal parameter values by their true values. While in practice not
a viable strategy, PI provides information on the value of perfect information, and allows us to
put the performance and differences between the other methods in perspective.
5.2 Study setup
The data set contains data from 17 liver patients treated with proton therapy at Massachusetts
General Hospital (Boston, USA). The mathematical models in Sections 3 and 4 are based on
the assumption that there is a single dose restricting OAR. We assume that the single dose
restricting OAR is the normal liver itself. For the models in Sections 3 and 4, an instance is
defined by a tuple (σ, ϕ,D, T,N1, Nmin, Nmax, dmin, dmax1 ) and the relevant uncertainty sets.
Clinically, the patients were treated with either 5 or 15 fractions. We extend the upper
bound to allow for more hyperfractionated treatments, and set Nmin = 5 and Nmax = 20. We
assume the biomarker acquisition is made once N1 = 4 fractions have been administered. This
implies Nmin2 = 1 and N
max
2 = 16. The mean OAR dose tolerances were derived for both a 5 and
a 15 fraction scheme (this is parameter T in the mathematical models). We pick T = 15, as this
will be more realistic for hyperfractionated treatments than the 5 fraction variant. The OAR
dose tolerance range corresponding with this scheme is D ∈ [20, 27]. Instead of directly using
the OAR dose distribution data from the 17 patients, we use it to generate a larger and more
heterogeneous set of phantom patient parameter tuples (σ, ϕ,D). For details see Appendix C.
We define two uncertainty sets for (ρ, τ). The α/β ratio for the normal liver in the data
set is 4, so we set nominal value ρ¯ = 0.25. The tumor α/β ratio in the data set is 10, but we
deviate from this. The reason is that condition (8) will not hold for any reasonable uncertainty
set for an α/β ratio of 10. In those cases, the optimal stage-2 fractionation is known a priori.
Therefore, we set nominal value τ¯ = 0.25, which corresponds to a nominal tumor α/β ratio of
4. In all numerical experiments we consider the two uncertainty sets of Table 2.
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Uncertainty Method
set NOM NOM-FH RO RO-FH ARO PI
1
Tumor BED - mean (Gy) 155.32 161.30 146.09 157.73 161.30 161.37
Tumor BED - 5% quantile (Gy) 126.30 130.33 127.77 130.53 130.33 130.65
Tumor BED - worst-case (Gy) 123.84 126.23 126.23 126.23 126.23 126.23
OAR violation - mean (%) 3.28 0 0 0 0 0
OAR violation - max (%) 12.31 0 0 0 0 0
Stage-1 dose d1 (Gy) 1.50 1.50 4.35 4.35 1.50 2.02
2
Tumor BED - mean (Gy) 155.66 163.32 146.30 159.42 163.32 163.46
Tumor BED - 5% quantile (Gy) 97.14 111.77 109.36 112.21 111.77 112.39
Tumor BED - worst-case (Gy) 91.65 105.91 105.91 105.91 105.91 105.91
OAR violation - mean (%) 3.33 0 0 0 0 0
OAR violation - max (%) 12.31 0 0 0 0 0
Stage-1 dose d1 (Gy) 1.50 1.50 4.35 4.35 1.50 2.13
Table 3: Results for experiments with exact biomarker observations and uniform sampling over Z. All
results are averages over a sample of SPOP = 50 patients. Per patient all reported statistics are computed
over a sample of size Sα/β = 200 of uncertain parameters τ and ρ from a uniform distribution over Z.
All methods optimize for worst-case tumor BED, which is displayed in bold.
To discriminate between multiple ARO solutions, we follow the procedure detailed in Sec-
tion 3.3 in case of exact biomarker data. The auxiliary scenarios are sampled uniformly from
int(Zmin) and int(Zmax). In case of inexact biomarker data, the procedure discussed in Section
4.3 is followed if the required auxiliary observations exist. If such observations exist, we sample
uniformly from Z until we have found two auxiliary observations for which any worst-case real-
ization is in int(Zmin) resp. int(Zmax). If such observations do not exist, the robustly optimal
solution to AIDP with lowest stage-1 dose is selected. The method RO (and therefore also RO-
FH) may also find multiple robustly optimal solutions. For the obtained set of robustly optimal
solutions we again follow the procedure detailed in Section 3.3. It turns out that for RO, the
robustly optimal solutions often perform identical in non-worst-case scenarios. We optimize over
the auxiliary scenarios consecutively; the first auxiliary scenario is the scenario corresponding
to int(Zmin).
The minimum dose per fraction is dmin = 1.5 Gy. For ARO the stage-1 upper bound dmax1
is set at the upper bound indicated by Assumptions 1 (for EDP) and 2 (for IDP). For RO,
parameter dmax1 is set such that it is feasible to deliver N
max
2 fractions with dose d
min in stage
2 in all scenarios in Z. For NOM (and NOM-FH) and PI parameter dmax1 is set such that
this is feasible under the nominal and true uncertainty scenario, respectively. Numerical results
indicate that results are not sensitive to the choice of dmin (and the corresponding dmax1 ).
First, Section 5.3 presents and discusses the results for the problem with exact biomarker
observations (EDP) of Section 3. After that, Section 5.4 presents and discusses the results
for the problem with inexact biomarker observations (IDP) of Section 4. Lastly, Section 5.5
again considers the inexact biomarker observation case, and varies parameter N1 in order to
determine the optimal moment of biomarker acquisition. All results are averages over a sample
of SPOP = 50 patients. All computations were performed on a 3.4Ghz Intel-Core i7 PC with
16GB RAM, using the software package MATLAB R2018b (Mathworks, Natick, MA, US).
5.3 Results exact biomarker observations
Table 3 presents the results. First, we find that adding the folding horizon component to the
static nominal and robust method improves the 5%-quantile and mean performance. For the
nominal method, including FH additionally leads to solutions that have no constraint violations
and improves the worst-case performance.
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All methods except NOM are worst-case optimal (i.e., RO resp. ARO for the static resp.
adjustable methods) in both scenarios. However, their mean performance differs, which implies
the existence of multiple worst-case solutions. Indeed, results in Table 3 indicate that these
methods have different stage-1 decisions d1. As indicated in Section 5.2, RO, RO-FH and ARO
optimize over auxiliary scenarios in this case; according to Theorem 2 ARO finds a PARO
solution this way. Mean tumor BED for ARO is 2.3% higher than for RO-FH and 10.4% higher
than for RO in uncertainty set 1.
Overall, methods that deliver a relatively low dose in stage-1 perform better on average than
the methods that deliver a relative high dose. This behavior can be explained as follows. For
scenarios where hypofractionation is optimal, it is optimal to deliver a low dose per fraction in
the first N1 = 4 fractions, and to deliver a single high dose fraction in fraction 5. This is the
best possible approximation for a single fraction treatment under the current set of constraints.
On the other hand, for scenarios where hyperfractionation is optimal, it is best to deliver an
intermediate dose per fraction throughout all N1 +Nmax2 = 20 fractions. Such treatments best
approximate a uniform fractionation scheme. The delivered dose is likely higher than dmin, but
not very high as it has to be delivered for a large number of fractions. The optimal stage-1 dose
best balances this trade-off.
In Table 3, the mean performance of ARO is slightly better than RO-FH, but equal to
NOM-FH. Indeed, their stage-1 decision is equal on average and in stage-2 they possess the
same information. The good performance of NOM-FH indicates that, in case of exact biomarker
information, ignoring uncertainty in stage 1 does not compromise mean performance nor leads
to OAR constraint violations. This observation, together with the fact that NOM has large
OAR constraint violations, shows that the value of (exact biomarker) information is high. If a
folding horizon step is included, solving the static robust problem in stage 1 even yields worse
solutions than when the static nominal problem is solved.
The difference between uncertainty sets 1 and 2 is mostly in a larger spread in performance:
For all methods both the worst-case and 5% quantile performance are lower in uncertainty set 2
than in uncertainty set 1, while mean performance is approximately equal. Note that the max-
imum violation percentage remains unchanged between the two scenarios because the bounds
on ρ remain unchanged, and this is the only parameter that influences the OAR constraint
violation. Furthermore, it is noteworthy that the average stage-1 decisions remain unchanged
for all methods as well. This underlines the limited influence of the uncertainty interval for τ .
The analyses in Section 3 (and 4 for inexact data) demonstrate that the main role of τ is to
determine the optimal N∗2 (ρ, τ), and that ρ plays a more important role.
Influence of multiple worst-case optimal solutions
To see the difference in mean performance between the multiple worst-case optimal solutions,
we compare PARO solution found by the ARO method to the ARO solution that performs worst
in the two auxiliary scenarios. Table 4 shows the results. The worst-performing ARO solution
has a considerably higher stage-1 dose. This implies that (for the current parameter settings)
delivering a high stage-1 dose does not allow as much adjustment possibilities in stage 2 as a low
stage-1 dose, but it does allow for adjustments to reach the worst-case optimum. Relative to
the results of Table 3, the difference between the best and worst ARO solution is considerable:
the worst-performing ARO solution is worse than the RO-FH solution. To see the influence of
the order of auxiliary scenarios for ARO, Table 5 additionally shows the results for ARO with
(ρaux-max, τaux-max) as the first auxiliary scenario (denoted AROaux-max). For the other methods
the order of auxiliary scenarios did not influence results. Results indicate that, in that case the
resulting PARO solution delivers 3.60 Gy per fraction in stage 1; this is a considerable difference
to the 1.50 Gy per fraction for AROaux-min. The mean tumor BED is higher for AROaux-min;
this is probably due to the fact that the majority of scenarios in Z were contained in Zmin, for
different parameter settings this may be opposite.
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Solution
AROworst ARObest
Tumor BED - mean (Gy) 155.06 161.30
Tumor BED - 5% quantile (Gy) 129.43 130.33
Tumor BED - worst-case (Gy) 126.23 126.23
Stage-1 dose d1 (Gy) 6.96 1.50
Table 4: Comparison between the best (PARO) and worst performing ARO solutions. Per patient all
reported statistics are computed over a sample of size Sα/β = 200 of uncertain parameters τ and ρ from
a uniform distribution over Z.
Method
AROaux-min AROaux-max
Tumor BED - mean (Gy) 161.30 158.57
Tumor BED - 5% quantile (Gy) 130.33 130.61
Tumor BED - worst-case (Gy) 126.23 126.23
Stage-1 dose d1 (Gy) 1.50 3.60
Table 5: Results for ARO for both orders of auxiliary scenarios. Method AROaux-min optimizes first
for (ρaux-min, τaux-min) and AROaux-max optimizes first for (ρaux-max, τaux-max). Results are displayed for
uncertainty set 1, uncertainty set 2 is similar. OAR constraint violations are zero in all cases.
Out-of-sample performance
To investigate the out-of-sample performance of the methods, we assume a uniform distribution
for (τ, ρ) over a larger set than Z. We can write Z as
Z = {(ρ, τ) : ρL ≤ ρ ≤ ρU , τL ≤ τ ≤ τU} = {(ρ, τ) : |ρ¯− ρ| ≤ ερ, |τ¯ − τ | ≤ ετ}, (34)
where (ερ, ετ ) is the maximum deviation from the nominal scenario (ρ¯, τ¯). This allows us to
define
Zc = {(ρ, τ) : |ρ¯− ρ| ≤ cερ, |τ¯ − τ | ≤ cετ}, (35)
where c > 0 is a parameter. We assume a uniform distribution over the new set Zc. If c = 1,
we have Zc = Z, so we sample exactly from Z. If c > 1, we sample from an interval that is c2
times as large as Z (c times larger for both τ and ρ). For c = 2 we obtain the results in Table
6. The stage-1 dose d1 is the same as in Table 3 for all methods except PI, because PI is the
only method that is aware that the samples are not taken from uncertainty set Z but from Z2.
For NOM, both the mean and maximum violation percentage has increased considerably. All
other methods were able to deal with the out-of-sample realizations and did not have any OAR
constraint violations.
None of the methods (other than PI) is worst-cast optimal. This implies that the worst-case
scenario of the experiments is a scenario outside of Z, because RO, RO-FH and ARO are optimal
for the worst-case realization in uncertainty set Z. RO-FH has marginally better worst-case
performance than ARO. The static methods NOM and RO have poor worst-case performance
compared to the adjustable methods, which indicates bad performance of the static methods on
scenarios outside of Z. Due to larger sampling space (the area of Z2 is four times the area of
Z) the difference between mean and worst-case performance is much larger than in Table 3 for
both scenarios and all methods.
In terms of average performance, ARO and NOM-FH stay close to PI, and the difference of
these methods with RO-FH is larger than in Table 3. Mean tumor BED for ARO is 8.0% higher
than for RO-FH and 37.2% higher than for RO in uncertainty set 1.
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Uncertainty Method
set NOM NOM-FH RO RO-FH ARO PI
1
Tumor BED - mean (Gy) 154.98 200.14 145.83 185.37 200.14 200.36
Tumor BED - 5% quantile (Gy) 99.28 114.48 110.73 114.91 114.48 115.22
Tumor BED - worst-case (Gy) 92.44 108.17 106.40 108.54 108.17 108.63
OAR violation - mean (%) 5.82 0 0 0 0 0
OAR violation - max (%) 20.68 0 0 0 0 0
Stage-1 dose d1 (Gy) 1.50 1.50 4.35 4.35 1.50 2.27
2
Tumor BED - mean (Gy) 156.18 203.11 146.64 188.09 203.11 203.50
Tumor BED - 5% quantile (Gy) 41.79 78.04 74.46 79.33 78.04 79.56
Tumor BED - worst-case (Gy) 28.38 68.57 65.97 69.29 68.57 69.45
OAR violation - mean (%) 5.75 0 0 0 0 0
OAR violation - max (%) 20.69 0 0 0 0 0
Stage-1 dose d1 (Gy) 1.50 1.50 4.35 4.35 1.50 2.32
Table 6: Results for experiments with exact biomarker observations and uniform sampling over Zc, with
c = 2. All results are averages over a sample of SPOP = 50 patients. Per patient all reported statistics are
computed over a sample of size Sα/β = 200 of uncertain parameters τ and ρ from a uniform distribution
over Zc. All methods optimize for worst-case tumor BED w.r.t. Z; displayed worst-case tumor BED is
w.r.t. Z2.
All together, the results from Table 3 show that, while all adjustable methods are worst-
case optimal and do not lead to constraint violations, some outperform others in non-worst-case
scenarios. Results from Table 6 imply that this difference is largest for realizations outside Z.
5.4 Results inexact biomarker observations
In the problem with in inexact biomarker information (IDP), we do not obtain the true parameter
values (ρ, τ) after N1 = 4 fractions, but only an estimate (ρˆ, τˆ ). As discussed in Section 4, we
specify a new uncertainty set Zˆ such that (ρˆ, τˆ)− (ρ, τ) ∈ Zˆ. Let DQ ∈ [0, 1] indicate the data
quality. Then we set Zˆ such that the width of the new uncertainty intervals for τ and ρ is
(1−DQ) times the width of the original intervals [τL, τU ] and [ρL, ρU ]. That is, DQ · 100% can
be interpreted as the percentage by which the uncertainty intervals can be reduced due to the
observation. The relation with the accuracy parameter rρ (or similarly rτ ) is given by
rρ =
1
2
(ρU − ρL)(1 −DQ). (36)
Note that even DQ = 0 has some value as the new interval is centered around the observation,
which already cuts off part of the original uncertainty set Z. We pick DQ = 2/3, so the
obtained information after fraction N1 reduces the size of the interval by 66.7% around the
new observation. Variations for DQ are considered in Section 5.5. For all patients the required
auxiliary scenarios for the method of Section 4.3 can be found. Table 7 shows the results. First,
we consider the nominal methods (NOM and NOM-FH). While NOM-FH performs better than
NOM on all performance measures, it performs considerably worse than in the cases with exact
biomarker information. Because any acquired biomarker information is now inexact, stage-2
adjustments are based on inexact data which makes them less valuable. For NOM-FH this leads
to (potentially large) OAR constraint violations of up to approximately 9% in terms of OAR
BED. Hence, in case of inexact biomarker information, robustness needs to be taken into account
from the start of stage 1.
In terms of worst-case performance, RO, RO-FH and ARO are equal to PI in both uncertainty
sets. This indicates that, although not theoretically guaranteed, ARO finds an ARO solution
in all considered scenarios. The mean performance of RO-FH and ARO is further away from
PI than in the case with exact biomarker information. This is as expected, as due to inexact
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Uncertainty Method
set NOM NOM-FH RO RO-FH ARO PI
1
Tumor BED - mean (Gy) 155.52 161.17 146.21 152.28 153.86 161.53
Tumor BED - 5% quantile (Gy) 126.46 130.24 127.87 129.15 129.08 130.69
Tumor BED - worst-case (Gy) 123.84 126.02 126.23 126.23 126.23 126.23
OAR violation - mean (%) 3.37 1.13 0 0 0 0
OAR violation - max (%) 12.31 9.10 0 0 0 0
Stage-1 dose d1 (Gy) 1.50 1.50 4.35 4.35 2.13 2.03
2
Tumor BED - mean (Gy) 155.09 162.40 145.95 152.93 154.72 162.96
Tumor BED - 5% quantile (Gy) 97.06 111.06 109.33 110.57 110.34 112.28
Tumor BED - worst-case (Gy) 91.65 103.14 105.91 105.91 105.91 105.91
OAR violation - mean (%) 3.31 1.10 0 0 0 0
OAR violation - max (%) 12.31 8.99 0 0 0 0
Stage-1 dose d1 (Gy) 1.50 1.50 4.35 4.35 2.08 2.12
Table 7: Results for experiments with inexact biomarker observations and data quality DQ = 2/3. All
results are averages over a sample of SPOP = 50 patients. Per patient all reported statistics are computed
over a sample of size Sα/β = 200 of uncertain parameters τ and ρ from a uniform distribution over Z.
All methods optimize for worst-case tumor BED, which is displayed in bold.
observations the possibility for ARO and RO-FH to make adjustments is less valuable, whereas
PI is not influenced by this. The same reasoning explains why RO is closer (but still worse on
all performance measures) to RO-FH than in Table 3.
ARO is the only method (together with PI) that has a different stage-1 decision than in the
case with exact biomarker information (Table 3). This is because it is the only method that
takes inexactness of biomarker data into account at the start of stage-1. The average stage-1
dose d1 differs considerably between ARO and RO-FH, whereas their worst-case performance
is equal on average (and equal to PI). This demonstrates the existence of multiple worst-case
optimal solutions. Whereas optimizing worst-case optimal solutions for ARO over two auxiliary
scenarios does not guarantee a PARO solution (see Section 4.3), results in Table 7 indicate that
it does yield solutions that performs slightly better on average than RO-FH (for the current
order of auxiliary scenarios).
5.5 Optimal moment of biomarker acquisition
We extend the previous experiment by varying the information point N1, and assuming a (hypo-
thetical) mathematical relationship between information point N1 and the data quality param-
eter DQ. With Nmax the maximum number of fractions, we consider the following three data
quality functions:
DQ1(N1) =
(
N1
Nmax
)4
(37a)
DQ2(N1) =
N1
Nmax
(37b)
DQ3(N1) =
(
N1
Nmax
)1/4
. (37c)
Hence, DQ1, DQ2 and DQ3 describe a convex, linear and concave relationship between obser-
vation moment and data quality, respectively. Figure 6 shows the graphs of the three functions.
Whether DQ1, DQ2 or DQ3 is most realistic depends on the specific biomarker(s) that is/are
used. For some biomarkers the data quality may greatly improve in the first few fractions,
with a diminishing improvement in later fractions, while for others, e.g., imaging biomarkers
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Figure 6: The biomarker data quality is a function of the number of delivered fractions N1 after which
it is acquired. We consider three functions DQi(N1), i = 1, 2, 3.
such as [18]F-FDG and [18]F-FLT, the data quality is poor at the first couple of fractions and
only increases substantially in later fractions. In practice, some biomarkers, e.g., radiographic
information (due to, for instance, interference from acute inflammation in the lung), may also
exhibit a decreasing data quality for high values of N1. Such behavior is rare, and as such
not considered here. Figure 7 shows the results for the numerical experiments where we varied
the information point N1 from 0 to Nmax − 1 for data quality functions DQi(N1), i = 1, 2, 3
and uncertainty sets 1 and 2 (see Table 2). It is important to note that as N1 increases past
Nmin = 5, this also increases the minimum number of fractions correspondingly.
First, we note that in all data quality functions and both uncertainty sets the method NOM-
FH has high mean tumor BED, but at the cost of high OAR tolerance violations. Hence, if
robustness is not taken into account at the start of stage 1, even a folding horizon method may
overdose the OARs.
Secondly, the performance of RO (the only static method) does not depend on N1, i.e.,
its curves in Figure 7 are approximately horizontal. This is as expected, as it does not use
the biomarker data at all. Both ARO and RO-FH perform better than RO due to the use of
biomarker information, and ARO performs better than RO-FH. In case of concave data quality
(most optimistic case, Figures 7e and 7f), these differences are most clearly observable. This
implies that there is value in (i) adapting based on acquired information, (ii) taking into account
that we can adapt later on when planning the stage-1 dose.
All figures demonstrate that the moment of biomarker acquisition influences the average
performance of all methods (except static RO). The optimal moment of biomarker acquisition
for PI is N1 = 4. This is because the minimum number of fractions is Nmin = 5. Hence, if
hypofractionation is optimal we can deliver one more fraction with high dose, and deliver a
low dose in the first four fractions. If hyperfractionation is optimal we can deliver 16 more
fractions (and get the total maximum of 20) with low dose. Note that PI does not actually
make an observation at N1, the choice of N1 solely determines what non-uniform treatments
PI can deliver due to the constant dose per stage restriction. Furthermore, having N1 > 4 also
implies that we force the use of more fractions than Nmin = 5, which is disadvantageous for
those scenarios where hypofractionation is optimal.
Figures 7e and 7f show that in case of concave data quality the optimal moment for biomarker
acquisition is between N1 = 6 and N1 = 10. Hence, due the inexactness of the biomarker data, it
is optimal to postpone the biomarker acquisition (compared to PI). The same effect is observable
if the data quality decreases even further. In case of linear data quality (Figures 7c and 7d) the
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(e) DQ3 (concave), uncertainty set 1
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Figure 7: Results for varying the information point N1 from 1 to Nmax − 1, for data quality functions
DQi(N1), i = 1, 2, 3 and uncertainty sets 1 and 2 (see Table 2). The OAR BED constraint violation (%)
of NOM-FH is measured against the right axis. Note that the mean tumor BED is displayed (measured
on the left axis), while the methods maximize the worst-case tumor BED.
optimal moment of biomarker acquisition is approximately between N1 = 12 and N1 = 14.
In case of convex data quality (Figures 7a and 7b) the optimal moment of biomarker acqui-
sition is between N1 = 16 and N1 = 20. As the maximum number of fractions is Nmax = 20, the
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optimal moment of observation is only a few fractions before the maximum number of fractions.
Observing later would severely limit the possibilities for adaptation. At N1 = 16, we force the
use of at least 17 fractions, also in the scenarios where it is optimal to hypofractionate. Never-
theless, current results indicate that such treatments are still preferred over a hypofractionated
treatment where the dose per fraction is based on very uncertain data.
To put the performance of all methods in perspective, we consider the results of PI. The
mean tumor BED for PI changes considerably with N1. There are two factors that influence
this: (i) as N1 increases the minimum number of fraction increases, which is disadvantageous for
those scenarios where hypofractionation is optimal, (ii) as we force a constant dose per stage,
the moment of observation also determines what type of nonuniform fractionation schemes we
can deliver. These two factors together lead to a difference in mean tumor BED of around 7 or
8 Gy between N1 = 4 and N1 = 19. In comparison, the maximum difference between ARO and
static RO is at most 9.8 Gy in mean tumor BED (concave data quality increase, uncertainty set
2).
Overall, there is a trade-off between early observation for fast adaptation and good data
quality. All plots for ARO and RO-FH in Figure 7 have a relatively flat top, indicating that
there is a range of preferred values for N1, rather than one clear best choice. Nevertheless,
results suggest that rate at which data quality improves has an effect on the optimal moment
of biomarker acquisition.
6 Concluding remarks
In case biomarker data is exact, the current model (EDP) has considerable ‘adjustment space’, so
it is not necessary to take robustness into account from the start. It is in particular noteworthy
that NOM-FH performs equal to ARO and better than RO-FH on average. In general this
suggests that static RO, even with a folding horizon, can be too conservative for two-stage
problems with exact data and sufficient adjustment space.
In case biomarker data is inexact, taking into account robustness from the start of stage 1 is
necessary to prevent OAR constraint violations in the current model (IDP). Another consequence
of inexactness of acquired biomarker data is that it postpones the optimal moment of biomarker
observation. By investigating several types of temporal changes in biomarker data quality, the
presented numerical results provide insight in the value of biomarker information quality and the
influence of biomarker acquisition time. This can guide the effort in acquiring useful biomarkers.
Next to the good numerical performance of ARO, one of its main benefits is that is provides
more insight into the optimal stage-2 decisions. In the current application, the optimal stage-2
decisions can be determined. Furthermore, in case of exact biomarker data ARO guarantees a
PARO solution, which is valuable due to the substantial difference in mean performance between
different ARO decisions. Although not guaranteed to be PARO, also in case of inexact biomarker
data ARO provides good performing solutions. To the best of our knowledge, we are the first to
introduce the PARO concept. Further research is needed to develop ways to construct PARO
solutions for general (linear) adjustable robust optimization.
The current setting can be extended in several ways. In practice the tumor and OAR α/β
values would have to be estimated from actual biomarkers (e.g., imaging, blood-based biomark-
ers, genotyping), which can be incorporated in the model. Furthermore, the approach can be
extended to heterogeneous tumor response (different α/β ratios for different tumor subvolumes).
To the best of our knowledge, we provide the first application of ARO in RT. Other RT applica-
tions may also benefit from ARO, such as re-optimization to account for organ motion or setup
errors, or optimization using the MR-linac.
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Appendix
A Extra analyses and proofs
For convenience, we repeat the definitions of functions B, g and f :
B(d′, N ′; ρ) := ϕD
(
1 +
ϕD
T
ρ
)
− σd1N1 − σ2ρd21N1 (A.1a)
g(d′, N ′, N ′′; ρ) :=
−1 +
√
1 + 4ρN ′′B(d
′, N ′; ρ)
2σρ
(A.1b)
f(d1, N2; ρ, τ) :=
{
N1d1 +N2g(d1, N1, N2; ρ) + τ
(
N1d
2
1 +N2g(d1, N1, N2; ρ)
2
)
if d1 ∈ [0, g(0, 0, N1 ; ρ)]
−∞ otherwise,
(A.1c)
see (9), (10) and (13).
A.1 Proof Theorem 1
First, we show that for fixed d1, feasible to (6) (or, equivalently, (14)) and given (ρ, τ), it is
optimal to minimize the number of stage-2 fractions if τ ≥ σρ, and it is optimal to maximize
the number of stage-2 fractions otherwise. After that, we show that N2(ρ, τ) = Nmin2 is feasible
if τ ≥ σρ and N2(ρ, τ) = Nmax2 is feasible otherwise.
Consider problem (6). At the start of stage 2, we have delivered N1 fractions with dose d1
per fraction. Let (ρ, τ) be the realization of the uncertain parameters. The stage-2 problem
reads
N1d1 + τN1d
2
1 + max
d2,N2
N2d2 + τN2d
2
2 (A.2a)
s.t. σN2d2 + ρσ
2N2d
2
2 ≤ B(d1, N1, ρ) (A.2b)
d2 ≥ dmin (A.2c)
N2 ∈ {Nmin2 , . . . , Nmax2 }. (A.2d)
This is a static fractionation problem. Constraint (A.2b) will hold with equality at the optimum,
because it is the only dose-limiting constraint. This allows us to rewrite the objective to
max
d2,N2
N2d2
(σρ− τ
σρ
)
+
τB(d1, N1, ρ)
σ2ρ
, (A.3)
which implies that if τ > σρ it is optimal to minimize d2N2. If τ < σρ it is optimal to maximize
d2N2, and if τ = σρ the objective value is independent of the value of N2. Similar results are
obtained in Mizuta et al. (2012), Bortfeld et al. (2015). As given in Section 3, at the optimum
N2d
∗
2(d1, N2; ρ) = N2g(d1, N1, N2; ρ) =
−N2 +
√
N22 + 4N2ρB(d1, N1; ρ)
2σρ
, (A.4)
and it is straightforward to show that
∂N2g(d1, N1, N2; ρ)
∂N2
≥ 0. (A.5)
Hence, if τ ≥ σρ, it is optimal to minimize the number of fractions, and if τ < σρ it is optimal
to maximize the number of fractions.
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For the second part, we must show that for any d1 and (ρ, τ) ∈ Zmin resp. (ρ, τ) ∈ Zmax, it
is indeed possible to deliver Nmin2 resp. N
max
2 fractions in stage 2. That is, we must show
g(d1, N1, N
min
2 ; ρ) ≥ dmin, ∀(ρ, τ) ∈ Zmin (A.6a)
g(d1, N1, N
max
2 ; ρ) ≥ dmin, ∀(ρ, τ) ∈ Zmax, (A.6b)
which is equivalent to
d1 ≤ g(dmin, Nmin2 , N1; ρ), ∀(ρ, τ) ∈ Zmin (A.7a)
d1 ≤ g(dmin, Nmax2 , N1; ρ), ∀(ρ, τ) ∈ Zmax. (A.7b)
Lemma 3a states that g is increasing or decreasing in ρ. Hence, it is sufficient to consider only
the largest and smallest value of ρ in Zmin and Zmax. Therefore, (A.7) is equivalent to
d1 ≤ g(dmin, Nmin2 , N1; ρL) (A.8a)
d1 ≤ g(dmin, Nmin2 , N1;
τL
σ
) (A.8b)
d1 ≤ g(dmin, Nmax2 , N1;
τL
σ
) (A.8c)
d1 ≤ g(dmin, Nmax2 , N1; ρU ). (A.8d)
From (A.1b) we see that function g is decreasing in its second argument, so (A.8b) is redundant.
The remaining three conditions in (A.8) hold true due to Assumption 1. Hence, a robustly
optimal decision for N2(·) is given by
N∗2 (ρ, τ) =
{
Nmin2 if τ ≥ σρ
Nmax2 otherwise.
(A.9)
In the scenario τ = σρ either decision may be taken.
A.2 Proof Theorem 2
Due to Theorem 1 it is sufficient to check whether conditions (21) hold for d1 ∈ XPARO with
N2(·) given by (16). If |XPARO| = 1, then this element is the only worst-case optimal solution
that is optimal in both auxiliary scenarios (ρaux-min, τaux-min) and (ρaux-max, τaux-max) so clearly
it is PARO. Hence, for the remainder of this proof we assume |XPARO| ≥ 2.
Consider Xaux-min. By construction of (ρaux-min, τaux-min) it holds that τaux-min 6= σρaux-min.
Hence, according to Lemma 4, there can be at most two values for d1 in Xaux-min that yield the
same objective value f , for a given scenario (ρ, τ) with τ 6= σρ. Hence, |Xaux-min| = |XPARO| = 2.
Denote the two elements of XPARO by d′1 and d
′′
1, let d
′
1 < d
′′
1 . Now, d
′
1 and d
′′
1 both solve (22)
and (23). Hence, according to Lemma 4, it holds that
d′′1 = t(d
′
1; ρ
aux-min, τaux-min) (A.10a)
d′′1 = t(d
′
1; ρ
aux-max, τaux-max). (A.10b)
From the definition of t (see (B.57)) we derive for σρ 6= τ :
∂t(d1; ρ, τ)
∂ρ
=
2N∗2 (ρ, τ)
N1 +N∗2 (ρ, τ)
∂g(d1, N1, N∗2 (ρ, τ); ρ)
∂ρ
, (A.11)
because N∗2 (ρ, τ) is constant in ρ unless σρ = τ . According to Lemma 3a, if for given N2 it
holds that d1 6= d−1 (N2) and d1 6= d+1 (N2) (defined in (B.38)), then function g(d1, N1, N2, ρ) is
strictly increasing or decreasing in ρ. By construction, it holds that d+1 (N2) = t(d
−
1 (N2), ρ) for
any ρ. According to Lemma 2b, it cannot hold that both d′1 = d
−
1 (N
min
2 and d
′
1 = d
−
1 (N
max
2 ).
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ρL ρU
τL
τU
(ρaux-min, τ aux-min)
(ρ1, τ1) (ρ2, τ2)
τ = σρ
ρ
τ
Figure 8: Case d′1 6= d−1 (Nmin2 ). Construction of two new scenarios (ρ1, τ1) and (ρ2, τ2) from scenario
(ρaux-min, τaux-min). Solution d′1 outperforms d
′′
1 at one scenario, vice versa at the other.
Additionally, it cannot hold that d′′1 = d
−
1 (N
min
2 ) or d
′′
1 = d
−
1 (N
max
2 ), because it would imply
d′′ ≤ d′. Hence, either d′1 6= d−1 (Nmin2 ) or d′1 6= d−1 (Nmax2 ) holds (or both).
We show that in either case, we can construct two new scenarios where d′1 outperforms d
′′
1
in one scenario, and vice versa in the other. Suppose d′1 6= d−1 (Nmin2 ). In this case, it holds that
∂t(d′1; ρ
aux-min, τaux-min)
∂ρ
6= 0. (A.12)
We consider two new scenarios. Let ε > 0 be a sufficiently small number and define
(ρ1, τ1) := (ρ
aux-min − ε, τaux-min) (∈ Zmin) (A.13a)
(ρ2, τ2) := (ρ
aux-min + ε, τaux-min). (∈ Zmin) (A.13b)
This is visualized in Figure 8. Due to (A.12) and (A.10a), it holds that(
t(d′1; ρ1, τ1) > d
′′ ∧ t(d′1; ρ2, τ2) < d′′
) ∨ (t(d′1; ρ1, τ1) < d′′ ∧ t(d′1; ρ2, τ2) > d′′). (A.14)
If the first clause is is true, we obtain
f(d′1, N
min
2 , ρ1, τ1) > f(d
′′
1, N
min
2 , ρ1, τ1) (A.15a)
f(d′1, N
min
2 , ρ2, τ2) < f(d
′′
1, N
min
2 , ρ2, τ2), (A.15b)
where we used convexity of f(d1, Nmin2 , ρ, τ) for (ρ, τ) ∈ Zmin. Similarly, if the second clause is
is true, we obtain
f(d′1, N
min
2 , ρ1, τ1) < f(d
′′
1, N
min
2 , ρ1, τ1) (A.16a)
f(d′1, N
min
2 , ρ2, τ2) > f(d
′′
1, N
min
2 , ρ2, τ2). (A.16b)
In either case, there is a scenario in Zmin where d′1 outperforms d
′′
1 and a scenario in Z
min where
d′′1 outperforms d
′
1. Hence, both d
′
1 and d
′′
1 are PARO. Using similar arguments, we can show
that in case d′1 6= d−1 (Nmax2 ) also both d′1 and d′′1 are PARO.
A.3 Proof Theorem 3
Consider problem (28). At the start of stage 2, we have delivered N1 fractions with dose d1
per fraction. Let (ρˆ, τˆ) be the observation. According to (24) and (26), the uncertainty set for
realization (ρ, τ) is given by
Zρˆ,τˆ :=
({(ρˆ, τˆ)}+ Zˆ) ∩ Z. (A.17)
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The resulting stage-2 problem for (28) reads
max
d2,N2
min
(ρ,τ)∈Zρˆ,τˆ
(N1d1 +N2d2) + τ(N1d
2
1 +N2d
2
2) (A.18a)
s.t. σN2d2 + ρσ
2N2d
2
2 ≤ B(d1, N1, ρ) ∀(ρ, τ) ∈ Zρˆ,τˆ (A.18b)
d2 ≥ dmin (A.18c)
N2 ∈ {Nmin2 , . . . , Nmax2 }. (A.18d)
This is a static robust optimization problem. Constraint (A.18b) will hold with equality at the
optimum, because it is the only dose-limiting constraint. Solving for d2 yields the constraint
d2 = g(d1, N1, N2; ρ), ∀(ρ, τ) ∈ Zρˆ,τˆ , (A.19)
and this is used to rewrite the objective (A.18a) can be written in terms of function f . Problem
(A.18) is equivalent to
max
N2
min
(ρ,τ)∈Zρˆ,τˆ
f(d1, N2, ρ, τ) (A.20a)
s.t. g(d1, N1, N2; ρ) ≥ dmin, ∀(ρ, τ) ∈ Zρˆ,τˆ (A.20b)
N2 ∈ {Nmin2 , . . . , Nmax2 }. (A.20c)
Uncertain parameter τ appears only in the objective, and function f is increasing in τ , so it is
sufficient to consider only those observations (ρ, τ) ∈ Zρˆ,τˆ with τ = τˆL. Additionally, according
to Lemma 3 functions f and g are increasing or decreasing in ρ. Hence, there are two candidate
worst-case scenarios: (ρˆL, τˆL) and (ρˆU , τˆL). We can rewrite (A.20) to
max
N2
min
{
f(d1, N2, ρˆL, τˆL), f(d1, N2, ρˆU , τˆL)
}
(A.21a)
s.t. g(d1, N1, N2; ρˆL) ≥ dmin (A.21b)
g(d1, N1, N2; ρˆU ) ≥ dmin (A.21c)
N2 ∈ {Nmin2 , . . . , Nmax2 }. (A.21d)
We distinguish three cases:
• Case (ρˆ, τˆ) ∈ ZmaxID : In this case, according to Theorem 1, any realization (ρ, τ) ∈ Zρˆ,τˆ is
such that N∗2 (ρ, τ) = N
max
2 . Constraints (A.21b) and (A.21c) reduce to
min
{
g(d1, N1, N
max
2 ; ρˆL), g(d1, N1, N
max
2 ; ρˆU )
} ≥ dmin, (A.22)
which is equivalent to
d1 ≤ min
{
g(dmin, Nmax2 , N1; ρˆL), g(d
min, Nmax2 , N1; ρˆU )
}
. (A.23)
It holds that ρˆL ≥ τˆLσ ≥ τLσ , and ρˆU ≤ ρU . According to Lemma 3a function g is either
increasing or decreasing in ρ for other arguments fixed. Hence, by Assumption 2 condition
(A.23) holds. Thus, (A.20) reduces to
min
{
f(d1, N
max
2 , ρˆL, τˆL), f(d1, N
max
2 , ρˆU , τˆL)
}
. (A.24)
By definition of f , this implies
d2 = min
{
g(d1, N1, N
max
2 ; ρˆL), g(d1, N1, N
max
2 ; ρˆU )
}
. (A.25)
29
• Case (ρˆ, τˆ) ∈ ZminID : In this case, according to Theorem 1, any realization (ρ, τ) ∈ Zρˆ,τˆ is
such that N∗2 (ρ, τ) = N
min
2 . Similar to the previous case, constraints (A.21b) and (A.21c)
reduce to
d1 ≤ min
{
g(dmin, Nmin2 , N1; ρˆL), g(d
min, Nmin2 , N1; ρˆU )
}
. (A.26)
It holds that ρˆL ≥ ρL, and ρˆU ≤ ρU . Hence, by Assumption 2, Lemma 3a and using the
fact that function g is decreasing in its second argument, condition (A.26) holds. Similar
to the previous case, we find
d2 = min
{
g(d1, N1, N
min
2 ; ρˆL), g(d1, N1, N
min
2 ; ρˆU )
}
. (A.27)
• Case (ρˆ, τˆ) ∈ Z intID : The optimal number of fractions in stage-2 is not known a priori. By
definition of Z intID , it holds that ρˆL ≥ τLσ − 2rρ and ρˆU ≤ ρU . By Assumption 2 it holds
that
d1 ≤ min
{
g(dmin, Nmax2 , N1;
τL
σ
− 2rρ, g(dmin, Nmax2 , N1; ρU )
}
. (A.28)
According to Lemma 3a function g is either increasing or decreasing in ρ, and function g
is decreasing in its third argument. Hence, (A.28) implies that (A.21b) and (A.21c) hold
for any feasible N2. Hence, problem (A.21) implies
N∗2 (d1; ρˆ, τˆ ) = argmax
N2∈{Nmin2 ,...,N
max
2
}
min
{
f(d1, N2, ρˆL, τˆL), f(d1, N2, ρˆU , τˆL)
}
, (A.29)
and by definition of f the corresponding value for d2 is
d2 = min
{
g(d1, N1, N
∗
2 (d1; ρˆ, τˆ ); ρˆL), g(d1, N1, N
∗
2 (d1; ρˆ, τˆ ); ρˆU )
}
. (A.30)
A.4 Extra analysis to Section 4
This analysis makes use of the lemmas in Appendix B. Consider problem (28). For given d1,
the optimal stage-2 decision rules are given by Theorem 3. As stated in Section 4, we split the
uncertainty set Z into three subsets. This enables us to exploit the fact that depending on (ρˆ, τˆ )
the value N∗2 (d1; ρˆ, τˆ) may be known in advance. The split (29) is repeated here for convenience
ZminID = {(ρˆ, τˆ) ∈ Z : τˆL ≥ σρˆU} (A.31a)
Z intID = {(ρˆ, τˆ) ∈ Z : σρˆL < τˆL < σρˆU} (A.31b)
ZmaxID = {(ρˆ, τˆ) ∈ Z : τˆL ≤ σρˆL}, (A.31c)
so that Z = ZminID ∪ Z intID ∪ ZmaxID . The associated uncertainty sets for (ρ, τ, ρˆ, τˆ ) are given by
U i = U ∩ {(ρ, τ, ρˆ, τˆ ) : (ρˆ, τˆ) ∈ ZiID}, i ∈ {min, int,max}, (A.32)
so it holds that U = Umin ∪ U int ∪ Umax. Set U i can be interpreted as the set of observation-
realization pairs for which the observation (ρˆ, τˆ ) is in set ZiID. Figure 4 illustrates the subsets Z
i
ID.
Set Umin consists of those observation-realization pairs (ρ, τ, ρˆ, τˆ) for which N∗2 (d1; ρˆ, τˆ ) = N
max
2 .
If (ρ, τ, ρˆ, τˆ) ∈ U int, then based on the observation (ρˆ, τˆ ) it is unclear what fractionation is
worst-case optimal. Last, if (ρ, τ, ρˆ, τˆ) ∈ Umax we know N∗2 (d1; (ρˆ, τˆ )) = Nmin2 . Problem (28) is
equivalent to
max
d1,τ
τ (A.33a)
s.t. τ ≤ f(d1, Nmin2 ; ρ, τ), ∀(ρ, τ, ρˆ, τˆ ) ∈ Umin (A.33b)
τ ≤ f(d1, N∗2 (d1; ρˆ, τˆ ); ρ, τ), ∀(ρ, τ, ρˆ, τˆ ) ∈ U int (A.33c)
τ ≤ f(d1, Nmax2 ; ρ, τ), ∀(ρ, τ, ρˆ, τˆ) ∈ Umax (A.33d)
dmin ≤ d1 ≤ dmax1 . (A.33e)
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Function f is increasing in τ , so for any decision (d1, d2, N2) the objective value improves if τ
increases. As such, for any worst case realization (ρ, τ), it holds that τ = τL. Therefore, any
observation with τˆ − rτ > τL cannot yield the worst-case realization. Define
U iL = Ui ∩ {(ρ, τ, ρˆ, τˆ ) : τˆ − rτ ≤ τL}, i ∈ {min, int,max}, (A.34)
which is the subset of U i of observation-realization pairs for which the realization of τ can be τL.
Therefore, in constraints (A.33b)-(A.33e) set U i can be replaced by U iL for i ∈ {min, int,max}.
For (A.33b) and (A.33d) it remains to find the worst-case realization of ρ for which the observation-
realization pair is in UminL and U
max
L , respectively. According to Lemma 3b, function f is in-
creasing or decreasing in ρ for fixed d1, so it is sufficient to check the maximum and minimum
realization of ρ for which the observation-realization pair is in those sets. These are
min{ρ : (ρ, τ, ρˆ, τˆ) ∈ UminL } = ρL, max{ρ : (ρ, τ, ρˆ, τˆ ) ∈ UminL } =
τL
σ
(A.35a)
min{ρ : (ρ, τ, ρˆ, τˆ) ∈ UmaxL } =
τL
σ
, max{ρ : (ρ, τ, ρˆ, τˆ) ∈ UmaxL } = ρU . (A.35b)
Plugging in ρ = τLσ in (A.33b) and (A.33d) yields τ ≤ K, with K defined by (19). Lemma 5
provides a conservative approximation of equation (A.33c). Putting everything together, the
following problem provides is lower bound of (A.33) (or, equivalently, (28)):
max
d1,τ
τ (A.36a)
s.t. τ ≤ f(d1, Nmin2 ; ρL, τL) (A.36b)
τ ≤ f(d1, Nmax2 ; ρU , τL) (A.36c)
τ ≤ K (A.36d)
τ ≤ p(d1) (A.36e)
dmin ≤ d1 ≤ dmax1 , (A.36f)
with p(d1) defined by (B.68) in Appendix B. Constraint (A.36e) is the only conservative con-
straint, all other constraints are exact reformulations. In particular, this means that if for a
solution the objective value equals K, it is certain that this is an optimal solution. It is easy to
obtain other straightforward conservative approximations of (A.33c). For instance, a policy that
delivers Nmin2 or N
max
2 fractions (or any number in between, for that matter) for any observation
(ρˆ, τˆ) ∈ Z intID is a conservative approximation. However, these perform less good and do not use
all information that is available, as demonstrated in the proof of Lemma 5.
B Extra lemmas
This appendix states and proves several frequently used properties of functions g and f .
Lemma 1 (Convexity/concavity f w.r.t. d1). Let ρ > 0, τ > 0 and N1, N2 ∈ N+. Let
d1 ∈ [0, g(0, 0, N1 ; ρ)]. The following properties hold for function f :
• Function f(d1, N2; ρ, τ) is strictly convex in d1 if τ > ρσ, with unique minimizer g(0, 0, N1+
N2; ρ);
• Function f(d1, N2; ρ, τ) is strictly concave in d1 if τ < ρσ, with unique maximizer g(0, 0, N1+
N2; ρ);
• Function f(d1, N2; ρ, τ) is constant in d1 if τ = ρσ, with value 1σB(0, 0, τσ ).
Proof. The partial derivative of f w.r.t. d1 is given by
∂f(d1, N2; ρ, τ)
∂d1
= N1 +N2
∂g(d1, N1, N2; ρ)
∂d1
+ τ
(
2N1d1 + 2N2g(d1, N1, N2; ρ)
∂g(d1, N1, N2; ρ)
∂d1
)
,
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where the partial derivative of g w.r.t. d1 is given by
∂g(d1, N1, N2; ρ)
∂d1
= − 1
N2
(N1 + 2N1d1σρ)
(
1 +
4ρ
N2
B(d1, N1; ρ)
)− 1
2
. (B.37)
Define h(d1, N2; ρ) = 1 + 4
ρ
N2
B(d1, N1; ρ). Then, plugging in (B.37), we obtain
∂f(d1, N2; ρ, τ)
∂d1
= (N1 − (N1 + 2N1d1σρ)h(d1, N2; ρ)−
1
2
+ τ
(
2N1d1 − 2
N2
(N1 + 2N1d1σρ)h(d1, N2; ρ)
− 1
2N2
−1 + h(d1, N2; ρ) 12
2σρ
)
=
N1
σρ
(
h(d1, N2; ρ)
− 1
2 (2σρd1 + 1)− 1
)
(τ − ρσ).
Further elementary math shows that h(d1, N2; ρ)−
1
2 (2σρd1 + 1) − 1 = 0 if and only if d1 =
g(0, 0, N1 +N2; ρ). For the second derivative of f w.r.t. d1 we obtain:
∂2f(d1, N2; ρ, τ)
∂d21
=
(τ − ρσ
σρ
N1
) ∂
∂d1
h(d1, N2; ρ)
− 1
2 (2σρd1 + 1)
=
(τ − ρσ
σρ
N1
)(
h(d1, N2; ρ)
− 1
2 2σρ+
2ρ
N2
(2σρd1 + 1)h(d1, N2, ρ)
− 3
2 (σN1 + 2ρσ
2d1N1)
)
,
and the second part of this product is positive. Hence, its sign depends only on the term τ −ρσ.
Combining the result for the first and second derivative, we obtain
• Function f(d1, N2; ρ, τ) is strictly convex in d1 if τ > ρσ, with unique minimizer g(0, 0, N1+
N2; ρ);
• Function f(d1, N2; ρ, τ) is strictly concave in d1 if τ < ρσ, with unique maximizer g(0, 0, N1+
N2; ρ);
• Function f(d1, N2; ρ, τ) is constant in d1 otherwise.
If τ = ρσ, we can rewrite f(d1, N2; τσ , τ) to
f(d1, N2;
τ
σ
, τ) = max
d2
{
d1N1 + d2N2 + τ(d
2
1N1 + d
2
2N2) | σ(d1N1 + d2N2) + ρσ2(d21N1 + d22N2) ≤ B(0, 0; ρ)
}
= max
d2
{
d1N1 + d2N2 + τ(d
2
1N1 + d
2
2N2) | σ(d1N1 + d2N2) + ρσ2(d21N1 + d22N2) = B(0, 0; ρ)
}
= max
d2
{
d1N1 + d2N2 + τ(d
2
1N1 + d
2
2N2) | d1N1 + d2N2 + τ(d21N1 + d22N2) =
1
σ
B(0, 0,
τ
σ
)
}
=
1
σ
B(0, 0,
τ
σ
).
Define
d−1 (N2) =


ϕD − ϕD
(
1 + (N1 +N2)N2−TN1T
) 1
2
σ(N1 +N2)
if N1 +N2 ≥ T ∧N1 ≤ T
−∞ otherwise
(B.38a)
d+1 (N2) =


ϕD + ϕD
(
1 + (N1 +N2)
N2−T
N1T
) 1
2
σ(N1 +N2)
if N1 +N2 ≥ T ∧N2 ≤ T
+∞ otherwise.
(B.38b)
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If two functions f with equal N2 but different ρ intersect, d1 takes value d
−
1 (N2) or d
+
1 (N2). The
following lemma provides information on the existence and location of these intersection points.
We consider only those values for d1 where function f(d1, N2; ρ, τ) is finite for all (ρ, τ) ∈ Z. Let
dUB = min
(ρ,τ)∈Z
g(0, 0, N1; ρ). (B.39)
Lemma 2 (Properties d−1 and d
+
1 ). Let N1, T ∈ N+.
(a) Let N2 ∈ N+. If ρ1 6= ρ2, the equation
f(d1, N2; ρ1, τ) = f(d1, N2; ρ2, τ), (B.40)
has the following real roots for d1 on the interval [0, dUB]:
• d−1 (N2) and d+1 (N2) if N1 +N2 ≥ T, N2 ≤ T and N1 ≤ T (B.41a)
• d−1 (N2) if N1 +N2 ≥ T, N2 ≤ T and N1 > T (B.41b)
• d+1 (N2) if N1 +N2 ≥ T, N2 > T and N1 ≤ T (B.41c)
• no roots on interval if N1 +N2 ≥ T, N2 > T and N1 > T (B.41d)
• no real roots otherwise. (B.41e)
(b) Let NA2 , N
B
2 ∈ N+ such that NA2 < NB2 . It holds that
( i) If d−1 (N
A
2 ) and d
−
1 (N
B
2 ) are both finite, then d
−
1 (N
A
2 ) > d
−
1 (N
B
2 );
( ii) If d+1 (N
A
2 ) and d
+
1 (N
B
2 ) are both finite, then d
+
1 (N
A
2 ) ≤ d+1 (NB2 ).
Proof. Both parts of the lemma are proved individually.
Proof part (a)
By definition of f , the equation f(d1, N2; ρ1, τ) = f(d1, N2; ρ2, τ) reduces to g(d1, N1, N2; ρ1) =
g(d1, N1, N2; ρ2) with d1 ∈ [0,min{g(0, 0, N1 ; ρ1), g(0, 0, N1 ; ρ2)}]. By construction of g, this
means we are interested in the pairs (d1, d2) that solve the system
σ(N1d1 +N2d2) + ρ1σ
2(N1d
2
1 +N2d
2
2) = ϕD(1 + ρ1
D
T
ϕ) (B.42a)
σ(N1d1 +N2d2) + ρ2σ
2(N1d
2
1 +N2d
2
2) = ϕD(1 + ρ2
D
T
ϕ) (B.42b)
d1 ≥ 0, d2 ≥ 0. (B.42c)
We subtract ρ2ρ1 times (B.42a) from (B.42b) and solve for d1 to obtain
d1 =
ϕD − σN2d2
σN1
. (B.43)
We know that d2 = g(d1, N1, N2; ρ1). Plugging in (B.43) in this expression and simplifying yields
the following roots for d2:
r−2 (N2) =
ϕD + ϕD
(
1 + (N1 +N2)
(N1
T − 1
)
/N2
) 1
2
σ(N1 +N2)
(B.44a)
r+2 (N2) =
ϕD − ϕD
(
1 + (N1 +N2)
(N1
T − 1
)
/N2
) 1
2
σ(N1 +N2)
. (B.44b)
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Plugging in (B.44) in (B.43) and simplifying yields
r−1 (N2) =
ϕD − ϕD
(
1 + (N1 +N2)
N2−T
N1T
) 1
2
σ(N1 +N2)
if N1 +N2 ≥ T ∧N1 ≤ T (B.45a)
r+1 (N2) =
ϕD + ϕD
(
1 + (N1 +N2)
N2−T
N1T
) 1
2
σ(N1 +N2)
if N1 +N2 ≥ T ∧N2 ≤ T. (B.45b)
These roots need not be real-valued, nor in the interval [0,min{g(0, 0, N1; ρ1), g(0, 0, N1 ; ρ2)}].
For both r−1 (N2) and r
+
1 (N2) to be real-valued, we require that
1 + (N1 +N2)
(N1
T
− 1)/N2 ≥ 0,
which reduces to N1+N2 ≥ T . Furthermore, for nonnegativity of r−1 (N2) and r+1 (N2) it suffices
to check nonnegativity of the former. This is equivalent to
ϕD − σN2d−2 ≥ 0,
which reduces to N2 ≤ T . Moreover, it needs to hold that r+1 (N2) ≤ g(0, 0, N1; ρ1) and r+1 (N2) ≤
g(0, 0, N1; ρ2). This is equivalent to r
+
2 (N2) ≥ 0, which can be rewritten to
1 + (N1 +N2)
(N1
T
− 1)/N2 ≤ 1,
and this reduces to N1 ≤ T . Parameters r−1 (N2) resp. r+1 (N2) (see (B.38)) take the values of
r−1 (N2) resp. r
−
1 (N2) if they are a root of (B.40), and −∞ resp. +∞ otherwise. All together,
we obtain the cases in (B.41).
It remains to show that the obtained roots are in the interval [0, dUB]. It is already shown
that, if they are (real-valued) roots to (B.40), then d−1 (N2), d
+
1 (N2) are nonnegative. Further-
more, in that case d−1 (N2) ≤ d+1 (N2). It holds that
∂g(0, 0, N1 ; ρ)
∂ρ
≤ 0⇔ N1 ≤ T.
Hence, if d+1 (N2) is a real-valued root to (B.40) it follows that
dUB = min
(ρ,τ)∈Z
g(0, 0, N1; ρ) ≥ lim
ρ→+∞
g(0, 0, N1; ρ) =
ϕD
σ
√
N1T
≥ d+1 (N2),
where the second equality follows from the definition of g. This implies that indeed d−1 (N2), d
+
1 (N2) ∈
[0, dUB].
Proof part (b)
Assume NA2 , N
B
2 ∈ N+ such that NA2 ≤ NB2 , and assume N1 +NA2 ≥ T . Statements (i) and (ii)
are proved individually.
Proof part (i)
Assume d−1 (N
A
2 ) and d
−
1 (N
B
2 ) are both finite. The denominator of d
−
1 (N2) (see (B.38a)) is in-
creasing in N2. The derivative (w.r.t. N2) of the part within the square root in the numerator of
(B.38a) is given by (N1T )−
1
2 (N1 + 2N2 − T ) ≥ 0, because N1 +N2 ≥ T . Hence, the numerator
is decreasing in N2, while the denominator is increasing in N2. This implies d
−
1 (N
A
2 ) > d
−
1 (N
B
2 ).
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Proof part (ii)
Assume d+1 (N
A
2 ) and d
+
1 (N
B
2 ) are both finite. One can show that
∂d+1 (N2)
∂N2
= ϕD
(N1 +N2)(N1 + 2N2 − T )− 2N1T
√
N2(N1+N2−T )
N1T
− 2N2(N1 +N2 − T )
2N1Tσ(N1 +N2)2
√
N2(N1+N2−T )
N1T
.
(B.46)
This implies
∂d+1 (N2)
∂N2
≥ 0
⇔ (N1 +N2)(N1 + 2N2 − T )− 2N1T
√
N2(N1 +N2 − T )
N1T
− 2N2(N1 +N2 − T ) ≥ 0
⇔ N1(N1 +N2 − T ) + TN2
2N1T
≥
√
N2(N1 +N2 − T )
N1T
⇔
(
N1(N1 +N2 − T ) + TN2
)2
4N21T
2
≥ N2(N1 +N2 − T )
N1T
⇔ (N1 − T )
2(N1 +N2)2
4N21T
2
≥ 0, (B.47)
where the fourth line is obtained by using the fact that N1 + N2 ≥ T , and squaring on both
sides. The last line follows from simple algebraic manipulations. Condition (B.47) clearly holds,
so d+1 (N
A
2 ) ≤ d+1 (NB2 ).
Lemma 3 (Derivative f and g w.r.t. ρ). Let (ρ, τ) ∈ Z.
(a) Let N ′, N ′′ ∈ N+. Let d′ ∈ [0, dUB]. If N ′ +N ′′ < T , then
∂g(d′, N ′, N ′′; ρ)
∂ρ
< 0 for all d′ ∈ [0, dUB]. (B.48)
If N ′ +N ′′ ≥ T , then
∂g(d′, N ′, N ′′; ρ)
∂ρ


< 0 if d′ ∈ [0, d−1 (N ′′)] ∪ [d+1 (N ′′), dUB]
= 0 if d′ ∈ [0, dUB] ∩ {d−1 (N ′′), d+1 (N ′′)}
> 0 if d′ ∈ [0, dUB] ∩ (d−1 (N ′′), d+1 (N ′′)).
(B.49)
(b) Let N1, N2 ∈ N+. Let d1 ∈ [0, dUB]. If N1 +N2 < T , then
∂f(d1, N2; ρ, τ)
∂ρ
< 0 for all d1 ∈ [0, dUB]. (B.50)
If N1 +N2 ≥ T , then
∂f(d1, N2; ρ, τ)
∂ρ


< 0 if d1 ∈ [0, d−1 (N2)] ∪ [d+1 (N2), dUB]
= 0 if d1 ∈ [0, dUB] ∩ {d−1 (N2), d+1 (N2)}
> 0 if d1 ∈ [0, dUB] ∩ (d−1 (N2), d+1 (N2)).
(B.51)
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Proof. We first prove part (a), after that the result of part (b) is easily obtained.
It holds that
∂g(d′, N ′, N ′′; ρ)
∂ρ
=
√
1 + 4ρN ′′B(d
′, N ′; ρ)− 1 + 2ρN ′′ (d′N ′σ − ϕD)
2σρ2
√
1 + 4ρN ′′B(d
′, N ′; ρ)
, (B.52)
so
∂g(d′, N ′, N ′′; ρ)
∂ρ
≥ 0⇔
√
(N ′′)2 + 4ρN ′′B(d′, N ′; ρ) ≥ N ′′ + 2ρ(ϕD − d′N ′σ). (B.53)
We distinguish 2 cases:
• ϕD < d′N ′σ. In this case, B(d′, N ′; ρ) > 0 only if N ′ > T . In this case, the delivered dose
exceeds the dose that is used to set the BED tolerance, which is only possible if the number
of fractions N ′ is strictly larger than the reference number of fractions T . Condition (B.53)
clearly holds, so g(d′, N ′, N ′′; ρ) is increasing in ρ. Using the fact that N ′ > T it is easily
shown that d−1 <
ϕD
σN ′ < d
′. Additionally, it can be shown that dUB < d
+
1 (N2).
• ϕD ≥ d′N ′σ. In this case, squaring (B.53) on both sides and simplifying results in
−σ2N ′(N ′ +N ′′)d′2 + 2ϕDN ′σd′ + (N ′′
T
− 1)ϕ2D2 ≥ 0, (B.54)
which is a condition independent of ρ. If N ′ + N ′′ < T , this inequality has no roots for
d′, and (B.54) holds for all d′ ∈ [0, N ′σϕD ]. If N ′ +N ′′ ≥ T one can verify that d1 = d−1 (N ′′)
and d1 = d
+
2 (N
′′) are the roots of this concave parabola if they are finite. The smaller
root, d−1 (N
′′), is finite if and only if N ′′ ≤ T . The larger root, d+1 (N ′′) is finite if and only
if N ′ ≤ T .
Putting all of the above together yields the required result for g, i.e., Lemma 3a.
The partial derivative of f w.r.t. ρ is given by
∂f(d1, N2; ρ, τ)
∂ρ
=
∂g(d′, N ′, N ′′; ρ)
∂ρ
(
N2 + 2τN2g(d1, N1, N2; ρ)
)
. (B.55)
Hence, the sign of the partial derivative of f w.r.t. ρ is equal to the sign of the partial derivative
of g w.r.t. ρ. This yields the result of Lemma 3b.
Let L,Q ∈ R+ denote the linear and quadratic contribution of d1 to f , i.e.,
L(d1, N2, ρ) := N1d1 +N2g(d1, N1, N2; ρ) (B.56a)
Q(d1, N2, ρ) := N1d
2
1 +N2g(d1, N1, N2; ρ)
2. (B.56b)
For given (ρ, τ) such that τ 6= σρ, define the twin point of d1 ∈W (ρ, τ) as
t(d1; ρ, τ) :=
(
N1 −N∗2 (ρ, τ)
)
d1 + 2N∗2 (ρ, τ)g
(
d1, N1, N
∗
2 (ρ, τ); ρ
)
N1 +N∗2 (ρ, τ)
, (B.57)
where
W (ρ, τ) :=
[
max{0, t(g(0, 0, N1 ; ρ); ρ, τ)}, min{t(0; ρ, τ), g(0, 0, N1 ; ρ)}
]
\{g(0, 0, N1 +N2; ρ)}.
(B.58)
Figure 9 illustrates the relation between d1 and t(d1; ρ, τ). The following lemma proves that for
fixed (ρ, τ) any d1 in the set W (ρ, τ) has a twin point t(d1; ρ, τ) that is also in the set W (ρ, τ),
and their objective values are equal.
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(a) Case t(0, ρ, τ) < g(0, 0, N1; ρ).
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(b) Case t(0, ρ, τ) > g(0, 0, N1; ρ).
Figure 9: Illustration of d1 and t(d1; ρ, τ), for convex f .
Lemma 4. Let (ρ, τ) ∈ Z, let N2 := N∗2 (ρ, τ) and let d1 ∈ [0, g(0, 0, N1 ; ρ)]. The system of
equations
L(d1;N2, ρ) = L(d
′
1;N2, ρ) (B.59a)
Q(d1;N2, ρ) = Q(d
′
1;N2, ρ) (B.59b)
has a solution d′1 ∈ [0, g(0, 0, N1 ; ρ)] that is unequal to d1 if and only if d1 ∈ W (ρ, τ). In that
case, the unique solution is d′1 = t(d1; ρ, τ) ∈ W (ρ, τ), and it holds that d1 = t(t(d1; ρ, τ); ρ, τ).
If additionally it holds that τ 6= σρ, then d′1 = t(d1; ρ, τ) is the unique solution to
f(d1, N2; ρ, τ) = f(d
′
1, N2; ρ, τ). (B.60)
Proof. Let (ρ, τ) such that τ 6= σρ, let N2 = N∗2 (ρ, τ). First, we show that if d1 ∈W (ρ, τ), then
(B.60) has a unique solution d′1 unequal to d1. Second, we show that if d1 /∈W (ρ, τ), then there
are no solutions d′1 to (B.60) unequal to d1.
For the first part, let d1 ∈ W (ρ). With L and Q defined in (B.56), f(d1, N2; ρ, τ) =
L(d1, N2; ρ) + τQ(d1, N2; ρ). Any d′1 that solves
L(d1, N2; ρ) = L(d
′
1, N2; ρ) (B.61a)
Q(d1, N2; ρ) = Q(d
′
1, N2; ρ), (B.61b)
has exactly the same objective value. Plug in definitions (B.56), rewrite the first equation to
eliminate g, and plug this in the second equation to get
d′1 =
L(d1, N2; ρ)±
√
N2
N1
(
(N1 +N2)Q(d1, N2; ρ)− L2(d1, N2; ρ)
)
N1 +N2
=
N1d1 +N2g(d1, N1, N2; ρ)±N2(d1 − g(d1, N1, N2; ρ))
N1 +N2
, (B.62)
where to obtain the second line we plugged in the definitions (B.56). The ‘+’ solution to (B.62)
returns d′1 = d1, and the ‘–’ solution returns
d′1 =
(N1 −N2)d1 + 2N2g(d1, N1, N2, ρ)
N1 +N2
, (B.63)
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and we denote this solution by t(d1; ρ, τ). By construction, it holds that d1 = t(t(d1; ρ, τ); ρ, τ).
Furthermore, it is easily shown that d1 = t(d1; ρ, τ) if and only if d1 = g(0, 0, N1+N2; ρ). Hence,
if d1 ∈ W (ρ, τ) there are two solutions to (B.61). Additionally, from (B.62) one can see that,
because the term d1 − g(d1, N1, N2, ρ) is increasing in d1, the function t(d1; ρ, τ) is decreasing in
d1. Consequently,
d1 ≤ min{t(0; ρ, τ), g(0, 0, N1 ; ρ)} ⇔ d′1 ≥ max{0, t(g(0, 0, N1 ; ρ); ρ, τ)}. (B.64)
Furthermore, using the same argument,
d1 ≥ max{0, t(g(0, 0, N1 ; ρ); ρ, τ)} ⇔ d′1 ≤ min{t(0; ρ, τ), g(0, 0, N1 ; ρ)}. (B.65)
Therefore, it holds that d′1 ∈W (ρ, τ).
Now, d1 and t(d1; ρ, τ) both solve (B.61) so their objective values are equal. Finally, this
implies that t(d1; ρ, τ) is a solution that is unequal to d1 that solves (B.60). It is also the unique
solution because if τ 6= σρ, function f(d1, N2; ρ, τ) is a strictly convex or concave function
according to Lemma 1, so f(d1, N2; ρ, τ) = z for some constant z ∈ R has either 0, 1 or 2
solutions.
For the second part of the proof, let d1 /∈ W (ρ, τ). It is easily shown that d1 = t(d1; ρ, τ) if
and only if d1 = g(0, 0, N1 +N2; ρ). Hence, in this case there is no solution d′1 ∈ [0, g(0, 0, N1 ; ρ)]
to (B.60) that is unequal to d1.
Suppose d1 > min{t(0; ρ, τ), g(0, 0, N1; ρ)}. Because d1 ∈ [0, g(0, 0, N1 ; ρ)], this implies
d1 > t(0, ρ, τ). As shown in the first part of the proof, it holds that d1 = t(t(d1; ρ, τ); ρ, τ). Hence,
d1 > t(0; ρ, τ) is equivalent to t(t(d1; ρ, τ), ρ, τ) > t(0; ρ, τ). Because t(d1; ρ, τ) is decreasing in
d1, this implies t(d1; ρ, τ) < 0. We have a contradiction, so if d1 > min{t(0; ρ, τ), g(0, 0, N1; ρ)}
there is no solution d′1 ∈ [0, g(0, 0, N1 ; ρ)] to (B.60) that is unequal to d1.
Similarly, if d1 < max{0, t(g(0, 0, N1; ρ); ρ, τ)} we also end up with a contradiction. This
completes the second part of the proof.
In the following lemma, let I(·|S) denote the indicator function for a set S:
I(x|S) =
{
1 if x ∈ S
0 otherwise.
(B.66)
Lemma 5. For given τ ∈ R+ and given d1 ∈ [0, dUB],
τ ≤ f(d1, N∗2 (d1; ρˆ, τˆ ); ρ, τ), ∀(ρ, τ, ρˆ, τˆ ) ∈ U intL , (B.67)
holds if τ ≤ p(d1), with
p(d1) =
∑
η∈{Nmin
2
,...,Nmax
2
}
max
{
f(d1, η; ρ
int
L , τL), f(d1, η − 1; ρintU , τL)
}
I(d1|Sη)
+ f(d1, N
min
2 ; ρ
int
L , τL)I(d1|Smin) + f(d1, Nmax2 ; ρintU , τL)I(d1|Smax),
(B.68)
where sets Smin, Smax and Sη are defined in (B.73a), (B.73d) and (B.78), respectively, and ρintL ,
ρintU are defined in (B.80).
Proof. By definition of N∗2 (d1; ρˆ, τˆ) and U
int
L , it holds that
τ ≤ f(d1, N∗2 (d1; ρˆ, τˆ ); ρ, τ), ∀(ρ, τ, ρˆ, τˆ) ∈ U intL , (B.69)
is equivalent to
τ ≤ max
η˜∈{Nmin
2
,...,Nmax
2
}
min{f(d1, η˜; ρˆL, τˆL), f(d1, η˜; ρˆU , τˆL)}, ∀(ρˆ, τˆ ) ∈ Z intID ∩ {(ρˆ, τˆ) : τˆ ≤ τL + rτ},
(B.70)
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and because function f is increasing in τ , we need to consider only those observations (ρˆ, τˆ )
with τˆL = τL. For the first part of the proof, we fix the observation (ρˆ, τˆ ), plug in τˆL = τL, and
rewrite (B.70) for this fixed observation.
Because (ρˆ, τˆ) ∈ Z intID , it holds that σρˆL < τL < σρˆU . Hence, by Lemma 1, function
f(d1, η, ρˆL, τL) is convex and f(d1, η, ρˆU , τL) is concave in d1 for any η ∈ N+. We make use of
results of Lemma 2. Define
E− = {η : N1 + η ≥ T, η ≤ T} ∩ {Nmin2 , . . . , Nmax2 } (B.71a)
E+ = {η : N1 + η ≥ T,N1 ≤ T} ∩ {Nmin2 , . . . , Nmax2 }, (B.71b)
and let η−min, η
−
max, η
+
min and η
+
max, denote the minima and maxima of these sets. If η ∈ E−
respectively η ∈ E+, then, according to Lemma 2a, d1 = d−1 (η) respectively d1 = d+1 (η) is a
nonnegative real root of
f(d1, η; ρˆL, τL) = f(d1, η; ρˆU , τL),
and the corresponding objective value equals K. From Lemma 2b we know that
d−1 (N
max
2 ) < . . . < d
−
1 (N
min
2 ) < d
+
1 (N
min
2 ) < . . . < d
+
1 (N
max
2 ). (B.72)
We use this to split the domain [0, dUB] as follows:
Smin =


[d−1 (η
−
min), d
+
1 (η
+
min)] if E
− 6= ∅, E+ 6= ∅
[0, d+1 (η
+
min)] if E
− = ∅, E+ 6= ∅
[d−1 (η
−
min), dUB] if E
− 6= ∅, E+ = ∅
∅ if N1 +Nmax2 < T
[0, dUB] otherwise
(B.73a)
S−η :=
{
[d−1 (η), d
−
1 (η − 1)] if η−min ≤ η − 1 < η ≤ η−max
∅ otherwise ∀η ∈ {N
min
2 + 1, . . . , N
max
2 } (B.73b)
S+η :=
{
[d+1 (η − 1), d+1 (η)] if η+min ≤ η − 1 < η ≤ η+max
∅ otherwise ∀η ∈ {N
min
2 + 1, . . . , N
max
2 } (B.73c)
Smax =


[0, d−1 (η
−
max)] ∪ [d+1 (η+max), dUB] if E− 6= ∅, E+ 6= ∅
[d+1 (η
+
max), dUB] if E
− = ∅, E+ 6= ∅
[0, d−1 (η
−
max)] if E
− 6= ∅, E+ = ∅
[0, dUB] if N1 +Nmax2 < T
∅ otherwise.
(B.73d)
We will reformulate (B.70) on each interval (set) separately, assuming it is nonempty.
1. “Smin”: If d1 ∈ Smin, then f(d1, η; ρˆL, τL) < f(d1, η; ρˆU , τL) for all η ∈ {Nmin2 , . . . , Nmax2 }
according to Lemma 3b, so it is optimal to deliver Nmin2 fractions. Hence, on this interval
(B.70) is equivalent to
τ ≤ f(d1, Nmin2 ; ρˆL, τL). (B.74)
2. “S−η ”: From Lemma 2a we know that f(d1, η, ρˆL, τL) = f(d1, η, ρˆU , τL) if d1 = d
−
1 (η) or
d1 = d
+
1 (η). In this case, their value equals K. Furthermore, function f(d1, η, ρˆL, τL) is
convex and f(d1, η, ρˆU , τL) is concave in d1. Consider the interval [d
−
1 (η), d
−
1 (η − 1)]. It
holds that
f(d1, η; ρˆL, τL) ≤ K ≤ f(d1, η − 1; ρˆL, τL) (B.75a)
f(d1, η − 1; ρˆU , τL) ≤ K ≤ f(d1, η; ρˆU , τL). (B.75b)
39
This implies that if d1 ∈ [d−1 (η), d−1 (η−1)], it is optimal to deliver either η or η−1 fractions.
If we deliver η fractions, the restricting worst-case scenario is (ρˆL, τL) and the value f is
above K for the scenario (ρˆU , τL). If we deliver η′ > η fractions, the value for the scenario
(ρˆL, τL) decreases, while the value for the scenario (ρˆU , τL) increases even further. Hence,
delivering η′ > η fractions cannot be optimal. Similarly, delivering less than η−1 fractions
cannot be optimal. Therefore, if d1 ∈ [d−1 (η), d−1 (η− 1)] it is optimal to deliver either η or
η − 1 fractions. This implies that on the interval S−η constraint (B.70) is equivalent to
τ ≤ max{f(d1, η; ρˆL, τL), f(d1, η − 1; ρˆU , τL)}. (B.76)
Note that this result does not depend on the values ρˆL and ρˆU , we only use that ρˆL <
τL
σ < ρˆU .
3. “S+η ”: Similar to the case for S
+
η , one can show that for d1 ∈ S+η constraint (B.70) is
equivalent to (B.76).
4. “Smax”: If d1 ∈ Smax, then f(d1, η; ρˆL, τL) > f(d1, η; ρˆU , τL) for all η ∈ {Nmin2 , . . . , Nmax2 }
according to Lemma 3b, so it is optimal to deliver Nmax2 fractions. Hence, on this interval
(B.70) is equivalent to
τ ≤ f(d1, Nmax2 ; ρˆU , τL). (B.77)
For sets S−η and S
+
η the reformulation is the same. Therefore, define
Sη = S
−
η ∪ S+η . (B.78)
Putting everything together, for d1 ∈ [0, dUB] the constraint (B.70) is equivalent to
τ ≤
∑
η∈{Nmin
2
,...,Nmax
2
}
max{f(d1, η; ρˆL, τL), f(d1, η − 1; ρˆU , τL)}I(d1|Sη)
+ f(d1, N
min
2 ; ρˆL, τL)I(d1|Smin) + f(d1, Nmax2 ; ρˆU , τL)I(d1|Smax), ∀(ρˆ, τˆ ) ∈ Z intID ∩ {(ρˆ, τˆ) : τˆ ≤ τL + rτ}.
(B.79)
In order to find a tractable conservative robust counterpart of (B.79), denote
ρintL = max{ρL,
τL
σ
− 2rρ} (B.80a)
ρintU = min{ρU ,
τL
σ
+ 2rρ}, (B.80b)
and note that ρintL ≤ ρˆL < τLσ < ρˆU ≤ ρintU . By Lemma 3b, it holds that function f is increasing
or decreasing in ρ for fixed d1, so
f(d1, η; ρˆL, τL) ≤ min{f(d1, η; ρintL , τL), f(d1, η;
τL
σ
, τL)}
= min{f(d1, η; ρintL , τL),K}
= f(d1, η; ρ
int
L , τL),
where the second equality follows from (B.75). A similar result holds for f(d1, η−1; ρˆU , τL). Fur-
thermore, as shown before, f is increasing in ρ on Smin and decreasing in ρ on Smax. Therefore,
a conservative approximation of (B.67) is given by
τ ≤
∑
η∈{Nmin
2
,...,Nmax
2
}
max{f(d1, η; ρintL , τL), f(d1, η − 1; ρintU , τL)}I(d1|Sη)
+ f(d1, N
min
2 ; ρ
int
L , τL)I(d1|Smin) + f(d1, Nmax2 ; ρintU , τL)I(d1|Smax),
(B.81)
and the RHS is p(d1).
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Figure 10: The graph of the fit (C.84), which relates the mean OAR dose sparing factor to the dose
shape for the liver patient population (solid line), along with 10% bounds (dashed and dotted lines).
Function p(d1) is a piece-wise function, on intervals defined by Smin and Smax it is convex and
concave, respectively. On any interval Sη function p(d1) is the maximum of a concave and con-
vex function.
C Details study setup
The data set contains data from 17 liver patients treated with proton therapy at Massachusetts
General Hospital (Boston, USA). All patients were treated with either 5 or 15 fractions. The
data is a subset of the data set used in Perkó et al. (2018), for more details on patient selection
we refer to that paper. We assume that the target is the gross tumor volume (GTV), and the
single dose restricting OAR is the healthy liver itself.
We generate a set of phantom patient parameters (tuples (σ, ϕ,D)) of size SPOP = 50. A
larger and more heterogeneous phantom patient sample allows for a better comparison between
ARO and the benchmark methods. Suppose the OAR consists of n voxels, with si the dose
sparing factor of voxel i. Let s¯ denote the relative mean OAR dose, i.e., the mean OAR dose
sparing factor:
s¯ =
1
n
n∑
i=1
si, (C.82)
and let ϕ denote the OAR dose shape factor, i.e.,
ϕ =
n
∑n
i=1 s
2
i(∑n
i=1 si
)2 , (C.83)
which is a measure for the dose heterogeneity, for details see Perkó et al. (2018). That paper
fits the relative mean OAR dose to the OAR dose shape factor using a two-term power series
model:
ϕ(s¯) = a(s¯)−b + c, (C.84)
where the fit to the data yields a = 0.339, b = 1.304 and c = 0.940, with an adjusted R2 of 0.987.
Figure 10 displays the graph of (C.84), along with 10% bounds. The set of phantom patient
parameters is generated based on (C.84). The mean OAR dose sparing factors in the data set
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are in the interval [0.08, 0.56]. We shift this to [0.2, 0.65]. This avoids the uninteresting cases
with very low OAR dose, which have a very high dose shape factor ϕ. Furthermore, it allows
us to test the performance on patients with a relatively high OAR dose, which are generally
more ‘complicated’ cases. We uniformly sample s¯ from [0.2, 0.65], and for every value of s¯, we
sample ϕ uniformly from the range [0.9ϕ(s¯), 1.1ϕ(s¯)]. The product of resulting ϕ and s¯ is the
generalized dose sparing factor σ for mean OAR BED:
σ = ϕs¯ =
∑n
i=1 s
2
i∑n
i=1 si
. (C.85)
By assuming a homogeneous dose distribution in the tumor, its generalized dose sparing factor
equals 1. To avoid (unrealistic) scenarios where the generalized dose sparing factor of the OAR
is larger than or equal to that of the tumor, we truncate σ at 1 − ǫ. Furthermore, we derive a
dose tolerance level D by uniform sampling from the interval [20, 27], which is the dose tolerance
range corresponding to the clinical 15 fraction scheme.
The entire procedure is summarized in Algorithm 1.
Algorithm 1: Generate phantom patient parameters
begin
Set γ = 0.1, s¯L = 0.2, s¯U = 0.65, DL = 20, DU = 27. Set SPOP = 50;
for p = 1 : SPOP do
Sample zs, zϕ, zD ∼ UNIF(0, 1);
Set s¯ = s¯L + (s¯U − s¯L)zs;
Set ϕL = ϕ(s¯)(1 − γ) and ϕU = ϕ(s¯)(1 + γ);
Set ϕ = ϕL + (ϕU − ϕL)zϕ and let σ = ϕs¯;
Set D = DL + (DU −DL)zD;
Parameters for phantom patient p are (σ, ϕ,D);
end
end
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